The effect of comb length on the in vitro and in vivo properties of self-assembled poly(oligoethylene glycol methacrylate)-based block copolymer nanoparticles

Comb copolymer analogues of poly(lactic acid)-polyethylene glycol block copolymers (PLA-b-PEG) offer potential to overcome the inherent chemistry and stability limitations of their linear block copolymer counterparts. Herein, we examine the differences between P(L)LA10K-b-PEG10K and linear-comb copolymer analogues thereof in which the linear PEG block is replaced by poly(oligo(ethylene glycol) methacrylate) (POEGMA) blocks with different side chain (comb) lengths but the same overall molecular weight. P(L)LA10K-b-POEGMA47510K and P(L)LA10K-b-POEGMA200010K block copolymers were synthesized via activators regenerated by electron transfer atom transfer radical polymerization (ARGET ATRP) and fabricated into self-assembled nanoparticles using flash nanoprecipitation via confined impinging jet mixing. Linear-comb copolymer analogues based on PLA-b-POEGMA yielded smaller but still well-controlled nanoparticle sizes (88 ± 2 nm and 114 ± 1 nm respectively compared to 159 ± 2 nm for P(L)LA10K-b-PEG10K nanoparticles) that exhibited improved colloidal stability relative to linear copolymer-based nanoparticles over a 15 day incubation period while maintaining comparably high cytocompatibility, although the comb copolymer analogues had somewhat lower loading capacity for doxorubicin hydrochloride. Cell spheroid studies showed that the linear-comb copolymers promoted enhanced tumor transport and thus cell killing compared to conventional linear block copolymers. In vivo studies showed all NP types could passively accumulate within implanted CT26 tumors but with different accumulation profiles, with P(L)LA10K-b-POEGMA200010K NPs showing continuous accumulation throughout the full 24 h monitoring period whereas tumor accumulation of P(L)LA10K-b-POEGMA47510K NPs was significant only between 8 h and 24 h. Overall, the linear-comb copolymer analogues exhibited superior stability, biodistribution, spheroid penetration, and inherent tunability over linear NP counterparts.

Exosomes From Human Umbilical Cord Stem Cells Suppress Macrophage-to-myofibroblast Transition, Alleviating Renal Fibrosis

Renal fibrosis, a progressive scarring of the kidney, lacks effective treatment. Human umbilical cord mesenchymal stem cell-derived exosomes (HucMSC-Exos) hold promise for treating kidney diseases due to their anti-inflammatory properties. This study investigates their potential to lessen renal fibrosis by targeting macrophage-to-myofibroblast transformation (MMT), a key driver of fibrosis. We employed a mouse model of unilateral ureteral obstruction (UUO) and cultured cells exposed to transforming growth factor-β (TGF-β) to mimic MMT. HucMSC-Exos were administered to UUO mice, and their effects on kidney function and fibrosis were assessed. Additionally, RNA sequencing and cellular analysis were performed to elucidate the mechanisms by which HucMSC-Exos inhibit MMT. HucMSC-Exos treatment significantly reduced kidney damage and fibrosis in UUO mice. They downregulated markers of fibrosis (Collagen I, vimentin, alpha-smooth muscle actin) and suppressed MMT (α-SMA + F4/80 + cells). Furthermore, ARNTL, a specific molecule, emerged as a potential target of HucMSC-Exos in hindering MMT and consequently preventing fibrosis. HucMSC-Exos effectively lessen renal fibrosis by suppressing MMT, suggesting a novel therapeutic strategy for managing kidney damage and fibrosis.

Pyroptosis activates conventional type I dendritic cells to mediate the priming of highly functional anticancer T cells

BACKGROUND

Initiation of antitumor immunity is reliant on the stimulation of dendritic cells (DCs) to present tumor antigens to naïve T cells and generate effector T cells that can kill cancer cells. Induction of immunogenic cell death after certain types of cytotoxic anticancer therapies can stimulate T cell-mediated immunity. However, cytotoxic therapies simultaneously activate multiple types of cellular stress and programmed cell death; hence, it remains unknown what types of cancer cell death confer superior antitumor immunity.

METHODS

Murine cancer cells were engineered to activate apoptotic or pyroptotic cell death after Dox-induced expression of procell death proteins. Cell-free supernatants were collected to measure secreted danger signals, cytokines, and chemokines. Tumors were formed by transplanting engineered tumor cells to specifically activate apoptosis or pyroptosis in established tumors and the magnitude of immune response measured by flow cytometry. Tumor growth was measured using calipers to estimate end point tumor volumes for Kaplan-Meier survival analysis.

RESULTS

We demonstrated that, unlike apoptosis, pyroptosis induces an immunostimulatory secretome signature. In established tumors pyroptosis preferentially activated CD103+ and XCR1+ type I conventional DCs (cDC1) along with a higher magnitude and functionality of tumor-specific CD8+ T cells and reduced number of regulatory T cells within the tumor. Depletion of cDC1 or CD4+ and CD8+ T cells ablated the antitumor response leaving mice susceptible to a tumor rechallenge.

CONCLUSION

Our study highlights that distinct types of cell death yield varying immunotherapeutic effect and selective activation of pyroptosis can be used to potentiate multiple aspects of the anticancer immunity cycle.

Observation of D^{+}→K_{S}^{0}a_{0}(980)^{+} in the Amplitude Analysis of D^{+}→K_{S}^{0}π^{+}η

We perform for the first time an amplitude analysis of the decay D^{+}→K_{S}^{0}π^{+}η and report the observation of the decay D^{+}→K_{S}^{0}a_{0}(980)^{+} using 2.93  fb^{-1} of e^{+}e^{-} collision data taken at a center-of-mass energy of 3.773 GeV with the BESIII detector. As the only W-annihilation-free decay among D to a_{0}(980) pseudoscalar, D^{+}→K_{S}^{0}a_{0}(980)^{+} is the ideal decay in extracting the contributions of the W-emission amplitudes involving a_{0}(980) and to study the final-state interactions. The absolute branching fraction of D^{+}→K_{S}^{0}π^{+}η is measured to be (1.27±0.04_{stat}±0.03_{syst})%. The branching fractions of intermediate processes D^{+}→K_{S}^{0}a_{0}(980)^{+} with a_{0}(980)^{+}→π^{+}η and D^{+}→π^{+}K[over ¯]_{0}^{*}(1430)^{0} with K[over ¯]_{0}^{*}(1430)^{0}→K_{S}^{0}η are measured to be (1.33±0.05_{stat}±0.04_{syst})% and (0.14±0.03_{stat}±0.01_{syst})%, respectively.

Observation of Significant Flavor-SU(3) Breaking in the Kaon Wave Function at 12<Q^{2}<25 GeV^{2} and Discovery of the Charmless Decay ψ(3770)→K_{S}^{0}K_{L}^{0}

We present cross sections for the reaction e^{+}e^{-}→K_{S}^{0}K_{L}^{0} at center-of-mass energies ranging from 3.51 to 4.95 GeV using data samples collected in the BESIII experiment, corresponding to a total integrated luminosity of 26.5  fb^{-1}. The ratio of neutral-to-charged kaon form factors at large momentum transfers (12 Collapse

Key Words Collapse

MESH Headings Collapse

Grants Collapse

Affiliation(s)

M Ablikim Institute of High Energy Physics, Beijing 100049, People's Republic of China
M N Achasov Budker Institute of Nuclear Physics SB RAS (BINP), Novosibirsk 630090, Russia
P Adlarson Uppsala University, Box 516, SE-75120 Uppsala, Sweden
X C Ai Zhengzhou University, Zhengzhou 450001, People's Republic of China
R Aliberti Johannes Gutenberg University of Mainz, Johann-Joachim-Becher-Weg 45, D-55099 Mainz, Germany
A Amoroso University of Turin and INFN, University of Turin, I-10125 Turin, Italy INFN, I-10125, Turin, Italy
M R An Liaoning Normal University, Dalian 116029, People's Republic of China
Q An State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Science and Technology of China, Hefei 230026, People's Republic of China
Y Bai Southeast University, Nanjing 211100, People's Republic of China
O Bakina Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
I Balossino INFN Sezione di Ferrara, INFN Sezione di Ferrara, I-44122 Ferrara, Italy
Y Ban Peking University, Beijing 100871, People's Republic of China
H-R Bao University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
V Batozskaya Institute of High Energy Physics, Beijing 100049, People's Republic of China National Centre for Nuclear Research, Warsaw 02-093, Poland
K Begzsuren Institute of Physics and Technology, Peace Avenue 54B, Ulaanbaatar 13330, Mongolia
N Berger Johannes Gutenberg University of Mainz, Johann-Joachim-Becher-Weg 45, D-55099 Mainz, Germany
M Berlowski National Centre for Nuclear Research, Warsaw 02-093, Poland
M Bertani INFN Laboratori Nazionali di Frascati, INFN Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
D Bettoni INFN Sezione di Ferrara, INFN Sezione di Ferrara, I-44122 Ferrara, Italy
F Bianchi University of Turin and INFN, University of Turin, I-10125 Turin, Italy INFN, I-10125, Turin, Italy
E Bianco University of Turin and INFN, University of Turin, I-10125 Turin, Italy INFN, I-10125, Turin, Italy
A Bortone University of Turin and INFN, University of Turin, I-10125 Turin, Italy INFN, I-10125, Turin, Italy
I Boyko Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
R A Briere Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
A Brueggemann University of Muenster, Wilhelm-Klemm-Strasse 9, 48149 Muenster, Germany
H Cai Wuhan University, Wuhan 430072, People's Republic of China
X Cai Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
A Calcaterra INFN Laboratori Nazionali di Frascati, INFN Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
G F Cao Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
N Cao Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
S A Cetin Turkish Accelerator Center Particle Factory Group, Istinye University, 34010 Istanbul, Turkey
J F Chang Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
T T Chang Xinyang Normal University, Xinyang 464000, People's Republic of China
W L Chang Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
G R Che Nankai University, Tianjin 300071, People's Republic of China
G Chelkov Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
C Chen Nankai University, Tianjin 300071, People's Republic of China
Chao Chen Soochow University, Suzhou 215006, People's Republic of China
G Chen Institute of High Energy Physics, Beijing 100049, People's Republic of China
H S Chen Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
M L Chen Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
S J Chen Nanjing University, Nanjing 210093, People's Republic of China
S L Chen North China Electric Power University, Beijing 102206, People's Republic of China
S M Chen Tsinghua University, Beijing 100084, People's Republic of China
T Chen Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
X R Chen Institute of Modern Physics, Lanzhou 730000, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
X T Chen Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
Y B Chen Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
Y Q Chen Jilin University, Changchun 130012, People's Republic of China
Z J Chen Hunan University, Changsha 410082, People's Republic of China
S K Choi Chung-Ang University, Seoul, 06974, Republic of Korea
X Chu Nankai University, Tianjin 300071, People's Republic of China
G Cibinetto INFN Sezione di Ferrara, INFN Sezione di Ferrara, I-44122 Ferrara, Italy
S C Coen Bochum Ruhr-University, D-44780 Bochum, Germany
F Cossio INFN, I-10125, Turin, Italy
J J Cui Shandong University, Jinan 250100, People's Republic of China
H L Dai Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
J P Dai Yunnan University, Kunming 650500, People's Republic of China
A Dbeyssi Helmholtz Institute Mainz, Staudinger Weg 18, D-55099 Mainz, Germany
R E de Boer Bochum Ruhr-University, D-44780 Bochum, Germany
D Dedovich Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
Z Y Deng Institute of High Energy Physics, Beijing 100049, People's Republic of China
A Denig Johannes Gutenberg University of Mainz, Johann-Joachim-Becher-Weg 45, D-55099 Mainz, Germany
I Denysenko Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
M Destefanis University of Turin and INFN, University of Turin, I-10125 Turin, Italy INFN, I-10125, Turin, Italy
F De Mori University of Turin and INFN, University of Turin, I-10125 Turin, Italy INFN, I-10125, Turin, Italy
B Ding Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Jinan, Jinan 250022, People's Republic of China
X X Ding Peking University, Beijing 100871, People's Republic of China
Y Ding Liaoning University, Shenyang 110036, People's Republic of China
Y Ding Jilin University, Changchun 130012, People's Republic of China
J Dong Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
L Y Dong Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
M Y Dong Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
X Dong Wuhan University, Wuhan 430072, People's Republic of China
M C Du Institute of High Energy Physics, Beijing 100049, People's Republic of China
S X Du Zhengzhou University, Zhengzhou 450001, People's Republic of China
Z H Duan Nanjing University, Nanjing 210093, People's Republic of China
P Egorov Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
Y H Fan North China Electric Power University, Beijing 102206, People's Republic of China
J Fang Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
S S Fang Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
W X Fang Institute of High Energy Physics, Beijing 100049, People's Republic of China
Y Fang Institute of High Energy Physics, Beijing 100049, People's Republic of China
Y Q Fang Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
R Farinelli INFN Sezione di Ferrara, INFN Sezione di Ferrara, I-44122 Ferrara, Italy
L Fava University of Eastern Piedmont, I-15121 Alessandria, Italy INFN, I-10125, Turin, Italy
F Feldbauer Bochum Ruhr-University, D-44780 Bochum, Germany
G Felici INFN Laboratori Nazionali di Frascati, INFN Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
C Q Feng State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Science and Technology of China, Hefei 230026, People's Republic of China
J H Feng Sun Yat-Sen University, Guangzhou 510275, People's Republic of China
K Fischer University of Oxford, Keble Road, Oxford OX13RH, United Kingdom
M Fritsch Bochum Ruhr-University, D-44780 Bochum, Germany
C D Fu Institute of High Energy Physics, Beijing 100049, People's Republic of China
J L Fu University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
Y W Fu Institute of High Energy Physics, Beijing 100049, People's Republic of China
H Gao University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
Y N Gao Peking University, Beijing 100871, People's Republic of China
Yang Gao State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Science and Technology of China, Hefei 230026, People's Republic of China
S Garbolino INFN, I-10125, Turin, Italy
I Garzia INFN Sezione di Ferrara, INFN Sezione di Ferrara, I-44122 Ferrara, Italy University of Ferrara, I-44122 Ferrara, Italy
P T Ge Wuhan University, Wuhan 430072, People's Republic of China
Z W Ge Nanjing University, Nanjing 210093, People's Republic of China
C Geng Sun Yat-Sen University, Guangzhou 510275, People's Republic of China
E M Gersabeck University of Manchester, Oxford Road, Manchester, M13 9PL, United Kingdom
A Gilman University of Oxford, Keble Road, Oxford OX13RH, United Kingdom
K Goetzen GSI Helmholtzcentre for Heavy Ion Research GmbH, D-64291 Darmstadt, Germany
L Gong Liaoning University, Shenyang 110036, People's Republic of China
W X Gong Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
W Gradl Johannes Gutenberg University of Mainz, Johann-Joachim-Becher-Weg 45, D-55099 Mainz, Germany
S Gramigna INFN Sezione di Ferrara, INFN Sezione di Ferrara, I-44122 Ferrara, Italy University of Ferrara, I-44122 Ferrara, Italy
M Greco University of Turin and INFN, University of Turin, I-10125 Turin, Italy INFN, I-10125, Turin, Italy
M H Gu Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
Y T Gu Guangxi University, Nanning 530004, People's Republic of China
C Y Guan Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
Z L Guan Henan University of Technology, Zhengzhou 450001, People's Republic of China
A Q Guo Institute of Modern Physics, Lanzhou 730000, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
L B Guo Nanjing Normal University, Nanjing 210023, People's Republic of China
M J Guo Shandong University, Jinan 250100, People's Republic of China
R P Guo Shandong Normal University, Jinan 250014, People's Republic of China
Y P Guo Fudan University, Shanghai 200433, People's Republic of China
A Guskov Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
J Gutierrez Indiana University, Bloomington, Indiana 47405, USA
T T Han Institute of High Energy Physics, Beijing 100049, People's Republic of China
W Y Han Liaoning Normal University, Dalian 116029, People's Republic of China
X Q Hao Henan Normal University, Xinxiang 453007, People's Republic of China
F A Harris University of Hawaii, Honolulu, Hawaii 96822, USA
K K He Soochow University, Suzhou 215006, People's Republic of China
K L He Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
F H H Heinsius Bochum Ruhr-University, D-44780 Bochum, Germany
C H Heinz Johannes Gutenberg University of Mainz, Johann-Joachim-Becher-Weg 45, D-55099 Mainz, Germany
Y K Heng Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
C Herold Suranaree University of Technology, University Avenue 111, Nakhon Ratchasima 30000, Thailand
T Holtmann Bochum Ruhr-University, D-44780 Bochum, Germany
P C Hong Fudan University, Shanghai 200433, People's Republic of China
G Y Hou Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
X T Hou Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
Y R Hou University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
Z L Hou Institute of High Energy Physics, Beijing 100049, People's Republic of China
B Y Hu Sun Yat-Sen University, Guangzhou 510275, People's Republic of China
H M Hu Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
J F Hu South China Normal University, Guangzhou 510006, People's Republic of China
T Hu Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
Y Hu Institute of High Energy Physics, Beijing 100049, People's Republic of China
G S Huang State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Science and Technology of China, Hefei 230026, People's Republic of China
K X Huang Sun Yat-Sen University, Guangzhou 510275, People's Republic of China
L Q Huang Institute of Modern Physics, Lanzhou 730000, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
X T Huang Shandong University, Jinan 250100, People's Republic of China
Y P Huang Institute of High Energy Physics, Beijing 100049, People's Republic of China
T Hussain University of the Punjab, Lahore-54590, Pakistan
N Hüsken Indiana University, Bloomington, Indiana 47405, USA Johannes Gutenberg University of Mainz, Johann-Joachim-Becher-Weg 45, D-55099 Mainz, Germany
N In der Wiesche University of Muenster, Wilhelm-Klemm-Strasse 9, 48149 Muenster, Germany
M Irshad State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Science and Technology of China, Hefei 230026, People's Republic of China
J Jackson Indiana University, Bloomington, Indiana 47405, USA
S Jaeger Bochum Ruhr-University, D-44780 Bochum, Germany
S Janchiv Institute of Physics and Technology, Peace Avenue 54B, Ulaanbaatar 13330, Mongolia
J H Jeong Chung-Ang University, Seoul, 06974, Republic of Korea
Q Ji Institute of High Energy Physics, Beijing 100049, People's Republic of China
Q P Ji Henan Normal University, Xinxiang 453007, People's Republic of China
X B Ji Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
X L Ji Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
Y Y Ji Shandong University, Jinan 250100, People's Republic of China
X Q Jia Shandong University, Jinan 250100, People's Republic of China
Z K Jia State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Science and Technology of China, Hefei 230026, People's Republic of China
H J Jiang Wuhan University, Wuhan 430072, People's Republic of China
P C Jiang Peking University, Beijing 100871, People's Republic of China
S S Jiang Liaoning Normal University, Dalian 116029, People's Republic of China
T J Jiang Hangzhou Normal University, Hangzhou 310036, People's Republic of China
X S Jiang Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
Y Jiang University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
J B Jiao Shandong University, Jinan 250100, People's Republic of China
Z Jiao Huangshan College, Huangshan 245000, People's Republic of China
S Jin Nanjing University, Nanjing 210093, People's Republic of China
Y Jin University of Jinan, Jinan 250022, People's Republic of China
M Q Jing Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
X M Jing University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
T Johansson Uppsala University, Box 516, SE-75120 Uppsala, Sweden
X Kui Institute of High Energy Physics, Beijing 100049, People's Republic of China
S Kabana Instituto de Alta Investigación, Universidad de Tarapacá, Casilla 7D, Arica 1000000, Chile
N Kalantar-Nayestanaki University of Groningen, NL-9747 AA Groningen, The Netherlands
X L Kang China University of Geosciences, Wuhan 430074, People's Republic of China
X S Kang Liaoning University, Shenyang 110036, People's Republic of China
M Kavatsyuk University of Groningen, NL-9747 AA Groningen, The Netherlands
B C Ke Zhengzhou University, Zhengzhou 450001, People's Republic of China
V Khachatryan Indiana University, Bloomington, Indiana 47405, USA
A Khoukaz University of Muenster, Wilhelm-Klemm-Strasse 9, 48149 Muenster, Germany
R Kiuchi Institute of High Energy Physics, Beijing 100049, People's Republic of China
R Kliemt GSI Helmholtzcentre for Heavy Ion Research GmbH, D-64291 Darmstadt, Germany
O B Kolcu Turkish Accelerator Center Particle Factory Group, Istinye University, 34010 Istanbul, Turkey
B Kopf Bochum Ruhr-University, D-44780 Bochum, Germany
M Kuessner Bochum Ruhr-University, D-44780 Bochum, Germany
A Kupsc National Centre for Nuclear Research, Warsaw 02-093, Poland Uppsala University, Box 516, SE-75120 Uppsala, Sweden
W Kühn Justus-Liebig-Universitaet Giessen, II. Physikalisches Institut, Heinrich-Buff-Ring 16, D-35392 Giessen, Germany
J J Lane University of Manchester, Oxford Road, Manchester, M13 9PL, United Kingdom
P Larin Helmholtz Institute Mainz, Staudinger Weg 18, D-55099 Mainz, Germany
A Lavania Indian Institute of Technology Madras, Chennai 600036, India
L Lavezzi University of Turin and INFN, University of Turin, I-10125 Turin, Italy INFN, I-10125, Turin, Italy
T T Lei State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Science and Technology of China, Hefei 230026, People's Republic of China
Z H Lei State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Science and Technology of China, Hefei 230026, People's Republic of China
H Leithoff Johannes Gutenberg University of Mainz, Johann-Joachim-Becher-Weg 45, D-55099 Mainz, Germany
M Lellmann Johannes Gutenberg University of Mainz, Johann-Joachim-Becher-Weg 45, D-55099 Mainz, Germany
T Lenz Johannes Gutenberg University of Mainz, Johann-Joachim-Becher-Weg 45, D-55099 Mainz, Germany
C Li Qufu Normal University, Qufu 273165, People's Republic of China
C Li Nankai University, Tianjin 300071, People's Republic of China
C H Li Liaoning Normal University, Dalian 116029, People's Republic of China
Cheng Li State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Science and Technology of China, Hefei 230026, People's Republic of China
D M Li Zhengzhou University, Zhengzhou 450001, People's Republic of China
F Li Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
G Li Institute of High Energy Physics, Beijing 100049, People's Republic of China
H Li State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Science and Technology of China, Hefei 230026, People's Republic of China
H B Li Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
H J Li Henan Normal University, Xinxiang 453007, People's Republic of China
H N Li South China Normal University, Guangzhou 510006, People's Republic of China
Hui Li Nankai University, Tianjin 300071, People's Republic of China
J R Li Tsinghua University, Beijing 100084, People's Republic of China
J S Li Sun Yat-Sen University, Guangzhou 510275, People's Republic of China
J W Li Shandong University, Jinan 250100, People's Republic of China
Ke Li Institute of High Energy Physics, Beijing 100049, People's Republic of China
L J Li Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
L K Li Institute of High Energy Physics, Beijing 100049, People's Republic of China
Lei Li Renmin University of China, Beijing 100872, People's Republic of China
M H Li Nankai University, Tianjin 300071, People's Republic of China
P R Li Lanzhou University, Lanzhou 730000, People's Republic of China
Q X Li Shandong University, Jinan 250100, People's Republic of China
S X Li Fudan University, Shanghai 200433, People's Republic of China
T Li Shandong University, Jinan 250100, People's Republic of China
W D Li Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
W G Li Institute of High Energy Physics, Beijing 100049, People's Republic of China
X H Li State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Science and Technology of China, Hefei 230026, People's Republic of China
X L Li Shandong University, Jinan 250100, People's Republic of China
Xiaoyu Li Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
Y G Li Peking University, Beijing 100871, People's Republic of China
Z J Li Sun Yat-Sen University, Guangzhou 510275, People's Republic of China
Z X Li Guangxi University, Nanning 530004, People's Republic of China
C Liang Nanjing University, Nanjing 210093, People's Republic of China
H Liang Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
H Liang State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Science and Technology of China, Hefei 230026, People's Republic of China
Y F Liang Sichuan University, Chengdu 610064, People's Republic of China
Y T Liang Institute of Modern Physics, Lanzhou 730000, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
G R Liao Guangxi Normal University, Guilin 541004, People's Republic of China
L Z Liao Shandong University, Jinan 250100, People's Republic of China
Y P Liao Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
J Libby Indian Institute of Technology Madras, Chennai 600036, India
A Limphirat Suranaree University of Technology, University Avenue 111, Nakhon Ratchasima 30000, Thailand
D X Lin Institute of Modern Physics, Lanzhou 730000, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
T Lin Institute of High Energy Physics, Beijing 100049, People's Republic of China
B J Liu Institute of High Energy Physics, Beijing 100049, People's Republic of China
B X Liu Wuhan University, Wuhan 430072, People's Republic of China
C Liu Jilin University, Changchun 130012, People's Republic of China
C X Liu Institute of High Energy Physics, Beijing 100049, People's Republic of China
F H Liu Shanxi University, Taiyuan 030006, People's Republic of China
Fang Liu Institute of High Energy Physics, Beijing 100049, People's Republic of China
Feng Liu Central China Normal University, Wuhan 430079, People's Republic of China
G M Liu South China Normal University, Guangzhou 510006, People's Republic of China
H Liu Lanzhou University, Lanzhou 730000, People's Republic of China
H B Liu Guangxi University, Nanning 530004, People's Republic of China
H M Liu Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
Huanhuan Liu Institute of High Energy Physics, Beijing 100049, People's Republic of China
Huihui Liu Henan University of Science and Technology, Luoyang 471003, People's Republic of China
J B Liu State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Science and Technology of China, Hefei 230026, People's Republic of China
J Y Liu Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
K Liu Institute of High Energy Physics, Beijing 100049, People's Republic of China
K Y Liu Liaoning University, Shenyang 110036, People's Republic of China
Ke Liu Henan University of Technology, Zhengzhou 450001, People's Republic of China
L Liu State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Science and Technology of China, Hefei 230026, People's Republic of China
L C Liu Nankai University, Tianjin 300071, People's Republic of China
Lu Liu Nankai University, Tianjin 300071, People's Republic of China
M H Liu Fudan University, Shanghai 200433, People's Republic of China
P L Liu Institute of High Energy Physics, Beijing 100049, People's Republic of China
Q Liu University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
S B Liu State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Science and Technology of China, Hefei 230026, People's Republic of China
T Liu Fudan University, Shanghai 200433, People's Republic of China
W K Liu Nankai University, Tianjin 300071, People's Republic of China
W M Liu State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Science and Technology of China, Hefei 230026, People's Republic of China
X Liu Lanzhou University, Lanzhou 730000, People's Republic of China
Y Liu Lanzhou University, Lanzhou 730000, People's Republic of China
Y Liu Zhengzhou University, Zhengzhou 450001, People's Republic of China
Y B Liu Nankai University, Tianjin 300071, People's Republic of China
Z A Liu Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
Z Q Liu Shandong University, Jinan 250100, People's Republic of China
X C Lou Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
F X Lu Sun Yat-Sen University, Guangzhou 510275, People's Republic of China
H J Lu Huangshan College, Huangshan 245000, People's Republic of China
J G Lu Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
X L Lu Institute of High Energy Physics, Beijing 100049, People's Republic of China
Y Lu Central South University, Changsha 410083, People's Republic of China
Y P Lu Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
Z H Lu Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
C L Luo Nanjing Normal University, Nanjing 210023, People's Republic of China
M X Luo Zhejiang University, Hangzhou 310027, People's Republic of China
T Luo Fudan University, Shanghai 200433, People's Republic of China
X L Luo Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
X R Lyu University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
Y F Lyu Nankai University, Tianjin 300071, People's Republic of China
F C Ma Liaoning University, Shenyang 110036, People's Republic of China
H Ma Yunnan University, Kunming 650500, People's Republic of China
H L Ma Institute of High Energy Physics, Beijing 100049, People's Republic of China
J L Ma Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
L L Ma Shandong University, Jinan 250100, People's Republic of China
M M Ma Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
Q M Ma Institute of High Energy Physics, Beijing 100049, People's Republic of China
R Q Ma Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
X Y Ma Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
Y Ma Peking University, Beijing 100871, People's Republic of China
Y M Ma Institute of Modern Physics, Lanzhou 730000, People's Republic of China
F E Maas Helmholtz Institute Mainz, Staudinger Weg 18, D-55099 Mainz, Germany
M Maggiora University of Turin and INFN, University of Turin, I-10125 Turin, Italy INFN, I-10125, Turin, Italy
S Malde University of Oxford, Keble Road, Oxford OX13RH, United Kingdom
Q A Malik University of the Punjab, Lahore-54590, Pakistan
A Mangoni INFN Sezione di Perugia, I-06100 Perugia, Italy
Y J Mao Peking University, Beijing 100871, People's Republic of China
Z P Mao Institute of High Energy Physics, Beijing 100049, People's Republic of China
S Marcello University of Turin and INFN, University of Turin, I-10125 Turin, Italy INFN, I-10125, Turin, Italy
Z X Meng University of Jinan, Jinan 250022, People's Republic of China
J G Messchendorp GSI Helmholtzcentre for Heavy Ion Research GmbH, D-64291 Darmstadt, Germany University of Groningen, NL-9747 AA Groningen, The Netherlands
G Mezzadri INFN Sezione di Ferrara, INFN Sezione di Ferrara, I-44122 Ferrara, Italy
H Miao Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
T J Min Nanjing University, Nanjing 210093, People's Republic of China
R E Mitchell Indiana University, Bloomington, Indiana 47405, USA
X H Mo Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
B Moses Indiana University, Bloomington, Indiana 47405, USA
N Yu Muchnoi Budker Institute of Nuclear Physics SB RAS (BINP), Novosibirsk 630090, Russia
J Muskalla Johannes Gutenberg University of Mainz, Johann-Joachim-Becher-Weg 45, D-55099 Mainz, Germany
Y Nefedov Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
F Nerling Helmholtz Institute Mainz, Staudinger Weg 18, D-55099 Mainz, Germany
I B Nikolaev Budker Institute of Nuclear Physics SB RAS (BINP), Novosibirsk 630090, Russia
Z Ning Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
S Nisar COMSATS University Islamabad, Lahore Campus, Defence Road, Off Raiwind Road, 54000 Lahore, Pakistan
Q L Niu Lanzhou University, Lanzhou 730000, People's Republic of China
W D Niu Soochow University, Suzhou 215006, People's Republic of China
Y Niu Shandong University, Jinan 250100, People's Republic of China
S L Olsen University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
Q Ouyang Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
S Pacetti INFN Sezione di Perugia, I-06100 Perugia, Italy University of Perugia, I-06100 Perugia, Italy
X Pan Soochow University, Suzhou 215006, People's Republic of China
Y Pan Southeast University, Nanjing 211100, People's Republic of China
A Pathak Jilin University, Changchun 130012, People's Republic of China
P Patteri INFN Laboratori Nazionali di Frascati, INFN Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
Y P Pei State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Science and Technology of China, Hefei 230026, People's Republic of China
M Pelizaeus Bochum Ruhr-University, D-44780 Bochum, Germany
H P Peng State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Science and Technology of China, Hefei 230026, People's Republic of China
Y Y Peng Lanzhou University, Lanzhou 730000, People's Republic of China
K Peters GSI Helmholtzcentre for Heavy Ion Research GmbH, D-64291 Darmstadt, Germany
J L Ping Nanjing Normal University, Nanjing 210023, People's Republic of China
R G Ping Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
S Plura Johannes Gutenberg University of Mainz, Johann-Joachim-Becher-Weg 45, D-55099 Mainz, Germany
V Prasad Instituto de Alta Investigación, Universidad de Tarapacá, Casilla 7D, Arica 1000000, Chile
F Z Qi Institute of High Energy Physics, Beijing 100049, People's Republic of China
H Qi State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Science and Technology of China, Hefei 230026, People's Republic of China
H R Qi Tsinghua University, Beijing 100084, People's Republic of China
M Qi Nanjing University, Nanjing 210093, People's Republic of China
T Y Qi Fudan University, Shanghai 200433, People's Republic of China
S Qian Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
W B Qian University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
C F Qiao University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
J J Qin University of South China, Hengyang 421001, People's Republic of China
L Q Qin Guangxi Normal University, Guilin 541004, People's Republic of China
X S Qin Shandong University, Jinan 250100, People's Republic of China
Z H Qin Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
J F Qiu Institute of High Energy Physics, Beijing 100049, People's Republic of China
S Q Qu Tsinghua University, Beijing 100084, People's Republic of China
C F Redmer Johannes Gutenberg University of Mainz, Johann-Joachim-Becher-Weg 45, D-55099 Mainz, Germany
K J Ren Liaoning Normal University, Dalian 116029, People's Republic of China
A Rivetti INFN, I-10125, Turin, Italy
M Rolo INFN, I-10125, Turin, Italy
G Rong Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
Ch Rosner Helmholtz Institute Mainz, Staudinger Weg 18, D-55099 Mainz, Germany
S N Ruan Nankai University, Tianjin 300071, People's Republic of China
N Salone National Centre for Nuclear Research, Warsaw 02-093, Poland
A Sarantsev Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
Y Schelhaas Johannes Gutenberg University of Mainz, Johann-Joachim-Becher-Weg 45, D-55099 Mainz, Germany
K Schoenning Uppsala University, Box 516, SE-75120 Uppsala, Sweden
M Scodeggio INFN Sezione di Ferrara, INFN Sezione di Ferrara, I-44122 Ferrara, Italy University of Ferrara, I-44122 Ferrara, Italy
K Y Shan Fudan University, Shanghai 200433, People's Republic of China
W Shan Hunan Normal University, Changsha 410081, People's Republic of China
X Y Shan State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Science and Technology of China, Hefei 230026, People's Republic of China
J F Shangguan Soochow University, Suzhou 215006, People's Republic of China
L G Shao Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
M Shao State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Science and Technology of China, Hefei 230026, People's Republic of China
C P Shen Fudan University, Shanghai 200433, People's Republic of China
H F Shen Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
W H Shen University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
X Y Shen Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
B A Shi University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
H C Shi State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Science and Technology of China, Hefei 230026, People's Republic of China
J L Shi Fudan University, Shanghai 200433, People's Republic of China
J Y Shi Institute of High Energy Physics, Beijing 100049, People's Republic of China
Q Q Shi Soochow University, Suzhou 215006, People's Republic of China
R S Shi Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
X Shi Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
J J Song Henan Normal University, Xinxiang 453007, People's Republic of China
T Z Song Sun Yat-Sen University, Guangzhou 510275, People's Republic of China
W M Song Institute of High Energy Physics, Beijing 100049, People's Republic of China Jilin University, Changchun 130012, People's Republic of China
Y J Song Fudan University, Shanghai 200433, People's Republic of China
Y X Song Peking University, Beijing 100871, People's Republic of China
S Sosio University of Turin and INFN, University of Turin, I-10125 Turin, Italy INFN, I-10125, Turin, Italy
S Spataro University of Turin and INFN, University of Turin, I-10125 Turin, Italy INFN, I-10125, Turin, Italy
F Stieler Johannes Gutenberg University of Mainz, Johann-Joachim-Becher-Weg 45, D-55099 Mainz, Germany
Y J Su University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
G B Sun Wuhan University, Wuhan 430072, People's Republic of China
G X Sun Institute of High Energy Physics, Beijing 100049, People's Republic of China
H Sun University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
H K Sun Institute of High Energy Physics, Beijing 100049, People's Republic of China
J F Sun Henan Normal University, Xinxiang 453007, People's Republic of China
K Sun Tsinghua University, Beijing 100084, People's Republic of China
L Sun Wuhan University, Wuhan 430072, People's Republic of China
S S Sun Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
T Sun Shanghai Jiao Tong University, Shanghai 200240, People's Republic of China
W Y Sun Jilin University, Changchun 130012, People's Republic of China
Y Sun China University of Geosciences, Wuhan 430074, People's Republic of China
Y J Sun State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Science and Technology of China, Hefei 230026, People's Republic of China
Y Z Sun Institute of High Energy Physics, Beijing 100049, People's Republic of China
Z T Sun Shandong University, Jinan 250100, People's Republic of China
Y X Tan State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Science and Technology of China, Hefei 230026, People's Republic of China
C J Tang Sichuan University, Chengdu 610064, People's Republic of China
G Y Tang Institute of High Energy Physics, Beijing 100049, People's Republic of China
J Tang Sun Yat-Sen University, Guangzhou 510275, People's Republic of China
Y A Tang Wuhan University, Wuhan 430072, People's Republic of China
L Y Tao University of South China, Hengyang 421001, People's Republic of China
Q T Tao Hunan University, Changsha 410082, People's Republic of China
M Tat University of Oxford, Keble Road, Oxford OX13RH, United Kingdom
J X Teng State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Science and Technology of China, Hefei 230026, People's Republic of China
V Thoren Uppsala University, Box 516, SE-75120 Uppsala, Sweden
W H Tian Shanxi Normal University, Linfen 041004, People's Republic of China
W H Tian Sun Yat-Sen University, Guangzhou 510275, People's Republic of China
Y Tian Institute of Modern Physics, Lanzhou 730000, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
Z F Tian Wuhan University, Wuhan 430072, People's Republic of China
I Uman Near East University, Nicosia, North Cyprus, 99138, Mersin 10, Turkey
Y Wan Soochow University, Suzhou 215006, People's Republic of China
S J Wang Shandong University, Jinan 250100, People's Republic of China
B Wang Institute of High Energy Physics, Beijing 100049, People's Republic of China
B L Wang University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
Bo Wang State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Science and Technology of China, Hefei 230026, People's Republic of China
C W Wang Nanjing University, Nanjing 210093, People's Republic of China
D Y Wang Peking University, Beijing 100871, People's Republic of China
F Wang University of South China, Hengyang 421001, People's Republic of China
H J Wang Lanzhou University, Lanzhou 730000, People's Republic of China
J P Wang Shandong University, Jinan 250100, People's Republic of China
K Wang Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
L L Wang Institute of High Energy Physics, Beijing 100049, People's Republic of China
M Wang Shandong University, Jinan 250100, People's Republic of China
Meng Wang Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
N Y Wang University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
S Wang Fudan University, Shanghai 200433, People's Republic of China
S Wang Lanzhou University, Lanzhou 730000, People's Republic of China
T Wang Fudan University, Shanghai 200433, People's Republic of China
T J Wang Nankai University, Tianjin 300071, People's Republic of China
W Wang Sun Yat-Sen University, Guangzhou 510275, People's Republic of China
W Wang University of South China, Hengyang 421001, People's Republic of China
W P Wang State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Science and Technology of China, Hefei 230026, People's Republic of China
X Wang Peking University, Beijing 100871, People's Republic of China
X F Wang Lanzhou University, Lanzhou 730000, People's Republic of China
X J Wang Liaoning Normal University, Dalian 116029, People's Republic of China
X L Wang Fudan University, Shanghai 200433, People's Republic of China
Y Wang Tsinghua University, Beijing 100084, People's Republic of China
Y D Wang North China Electric Power University, Beijing 102206, People's Republic of China
Y F Wang Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
Y L Wang Henan Normal University, Xinxiang 453007, People's Republic of China
Y N Wang North China Electric Power University, Beijing 102206, People's Republic of China
Y Q Wang Institute of High Energy Physics, Beijing 100049, People's Republic of China
Yaqian Wang Institute of High Energy Physics, Beijing 100049, People's Republic of China Hebei University, Baoding 071002, People's Republic of China
Yi Wang Tsinghua University, Beijing 100084, People's Republic of China
Z Wang Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
Z L Wang University of South China, Hengyang 421001, People's Republic of China
Z Y Wang Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
Ziyi Wang University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
D Wei University of Science and Technology Liaoning, Anshan 114051, People's Republic of China
D H Wei Guangxi Normal University, Guilin 541004, People's Republic of China
F Weidner University of Muenster, Wilhelm-Klemm-Strasse 9, 48149 Muenster, Germany
S P Wen Institute of High Energy Physics, Beijing 100049, People's Republic of China
C W Wenzel Bochum Ruhr-University, D-44780 Bochum, Germany
U Wiedner Bochum Ruhr-University, D-44780 Bochum, Germany
G Wilkinson University of Oxford, Keble Road, Oxford OX13RH, United Kingdom
M Wolke Uppsala University, Box 516, SE-75120 Uppsala, Sweden
L Wollenberg Bochum Ruhr-University, D-44780 Bochum, Germany
C Wu Liaoning Normal University, Dalian 116029, People's Republic of China
J F Wu Institute of High Energy Physics, Beijing 100049, People's Republic of China China Center of Advanced Science and Technology, Beijing 100190, People's Republic of China
L H Wu Institute of High Energy Physics, Beijing 100049, People's Republic of China
L J Wu Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
X Wu Fudan University, Shanghai 200433, People's Republic of China
X H Wu Jilin University, Changchun 130012, People's Republic of China
Y Wu University of Science and Technology of China, Hefei 230026, People's Republic of China
Y H Wu Soochow University, Suzhou 215006, People's Republic of China
Y J Wu Institute of Modern Physics, Lanzhou 730000, People's Republic of China
Z Wu Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
L Xia State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Science and Technology of China, Hefei 230026, People's Republic of China
X M Xian Liaoning Normal University, Dalian 116029, People's Republic of China
T Xiang Peking University, Beijing 100871, People's Republic of China
D Xiao Lanzhou University, Lanzhou 730000, People's Republic of China
G Y Xiao Nanjing University, Nanjing 210093, People's Republic of China
S Y Xiao Institute of High Energy Physics, Beijing 100049, People's Republic of China
Y L Xiao Fudan University, Shanghai 200433, People's Republic of China
Z J Xiao Nanjing Normal University, Nanjing 210023, People's Republic of China
C Xie Nanjing University, Nanjing 210093, People's Republic of China
X H Xie Peking University, Beijing 100871, People's Republic of China
Y Xie Shandong University, Jinan 250100, People's Republic of China
Y G Xie Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
Y H Xie Central China Normal University, Wuhan 430079, People's Republic of China
Z P Xie State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Science and Technology of China, Hefei 230026, People's Republic of China
T Y Xing Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
C F Xu Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
C J Xu Sun Yat-Sen University, Guangzhou 510275, People's Republic of China
G F Xu Institute of High Energy Physics, Beijing 100049, People's Republic of China
H Y Xu University of Jinan, Jinan 250022, People's Republic of China
Q J Xu Hangzhou Normal University, Hangzhou 310036, People's Republic of China
Q N Xu Inner Mongolia University, Hohhot 010021, People's Republic of China
W Xu Institute of High Energy Physics, Beijing 100049, People's Republic of China
W L Xu University of Jinan, Jinan 250022, People's Republic of China
X P Xu Soochow University, Suzhou 215006, People's Republic of China
Y C Xu Yantai University, Yantai 264005, People's Republic of China
Z P Xu Nanjing University, Nanjing 210093, People's Republic of China
Z S Xu University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
F Yan Fudan University, Shanghai 200433, People's Republic of China
L Yan Fudan University, Shanghai 200433, People's Republic of China
W B Yan State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Science and Technology of China, Hefei 230026, People's Republic of China
W C Yan Zhengzhou University, Zhengzhou 450001, People's Republic of China
X Q Yan Institute of High Energy Physics, Beijing 100049, People's Republic of China
H J Yang Shanghai Jiao Tong University, Shanghai 200240, People's Republic of China
H L Yang Jilin University, Changchun 130012, People's Republic of China
H X Yang Institute of High Energy Physics, Beijing 100049, People's Republic of China
Tao Yang Institute of High Energy Physics, Beijing 100049, People's Republic of China
Y Yang Fudan University, Shanghai 200433, People's Republic of China
Y F Yang Nankai University, Tianjin 300071, People's Republic of China
Y X Yang Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
Yifan Yang Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
Z W Yang Lanzhou University, Lanzhou 730000, People's Republic of China
Z P Yao Shandong University, Jinan 250100, People's Republic of China
M Ye Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
M H Ye China Center of Advanced Science and Technology, Beijing 100190, People's Republic of China
J H Yin Institute of High Energy Physics, Beijing 100049, People's Republic of China
Z Y You Sun Yat-Sen University, Guangzhou 510275, People's Republic of China
B X Yu Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
C X Yu Nankai University, Tianjin 300071, People's Republic of China
G Yu Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
J S Yu Hunan University, Changsha 410082, People's Republic of China
T Yu University of South China, Hengyang 421001, People's Republic of China
X D Yu Peking University, Beijing 100871, People's Republic of China
C Z Yuan Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
L Yuan Beihang University, Beijing 100191, People's Republic of China
S C Yuan Institute of High Energy Physics, Beijing 100049, People's Republic of China
Y Yuan Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
Z Y Yuan Sun Yat-Sen University, Guangzhou 510275, People's Republic of China
C X Yue Liaoning Normal University, Dalian 116029, People's Republic of China
A A Zafar University of the Punjab, Lahore-54590, Pakistan
F R Zeng Shandong University, Jinan 250100, People's Republic of China
S H Zeng University of South China, Hengyang 421001, People's Republic of China
X Zeng Fudan University, Shanghai 200433, People's Republic of China
Y Zeng Hunan University, Changsha 410082, People's Republic of China
Y J Zeng Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
X Y Zhai Jilin University, Changchun 130012, People's Republic of China
Y C Zhai Shandong University, Jinan 250100, People's Republic of China
Y H Zhan Sun Yat-Sen University, Guangzhou 510275, People's Republic of China
A Q Zhang Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
B L Zhang Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
B X Zhang Institute of High Energy Physics, Beijing 100049, People's Republic of China
D H Zhang Nankai University, Tianjin 300071, People's Republic of China
G Y Zhang Henan Normal University, Xinxiang 453007, People's Republic of China
H Zhang University of Science and Technology of China, Hefei 230026, People's Republic of China
H C Zhang Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
H H Zhang Sun Yat-Sen University, Guangzhou 510275, People's Republic of China
H H Zhang Jilin University, Changchun 130012, People's Republic of China
H Q Zhang Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
H Y Zhang Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
J Zhang Sun Yat-Sen University, Guangzhou 510275, People's Republic of China
J Zhang Zhengzhou University, Zhengzhou 450001, People's Republic of China
J J Zhang Shanxi Normal University, Linfen 041004, People's Republic of China
J L Zhang Henan University, Kaifeng 475004, People's Republic of China
J Q Zhang Nanjing Normal University, Nanjing 210023, People's Republic of China
J W Zhang Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
J X Zhang Lanzhou University, Lanzhou 730000, People's Republic of China
J Y Zhang Institute of High Energy Physics, Beijing 100049, People's Republic of China
J Z Zhang Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
Jianyu Zhang University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
L M Zhang Tsinghua University, Beijing 100084, People's Republic of China
L Q Zhang Sun Yat-Sen University, Guangzhou 510275, People's Republic of China
Lei Zhang Nanjing University, Nanjing 210093, People's Republic of China
P Zhang Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
Q Y Zhang Liaoning Normal University, Dalian 116029, People's Republic of China Zhengzhou University, Zhengzhou 450001, People's Republic of China
Shuihan Zhang Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
Shulei Zhang Hunan University, Changsha 410082, People's Republic of China
X D Zhang North China Electric Power University, Beijing 102206, People's Republic of China
X M Zhang Institute of High Energy Physics, Beijing 100049, People's Republic of China
X Y Zhang Shandong University, Jinan 250100, People's Republic of China
Y Zhang University of South China, Hengyang 421001, People's Republic of China
Y Zhang University of Oxford, Keble Road, Oxford OX13RH, United Kingdom
Y T Zhang Zhengzhou University, Zhengzhou 450001, People's Republic of China
Y H Zhang Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
Yan Zhang State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Science and Technology of China, Hefei 230026, People's Republic of China
Yao Zhang Institute of High Energy Physics, Beijing 100049, People's Republic of China
Z D Zhang Institute of High Energy Physics, Beijing 100049, People's Republic of China
Z H Zhang Institute of High Energy Physics, Beijing 100049, People's Republic of China
Z L Zhang Jilin University, Changchun 130012, People's Republic of China
Z Y Zhang Nankai University, Tianjin 300071, People's Republic of China
Z Y Zhang Wuhan University, Wuhan 430072, People's Republic of China
G Zhao Institute of High Energy Physics, Beijing 100049, People's Republic of China
J Y Zhao Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
J Z Zhao Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
Lei Zhao State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Science and Technology of China, Hefei 230026, People's Republic of China
Ling Zhao Institute of High Energy Physics, Beijing 100049, People's Republic of China
M G Zhao Nankai University, Tianjin 300071, People's Republic of China
R P Zhao University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
S J Zhao Zhengzhou University, Zhengzhou 450001, People's Republic of China
Y B Zhao Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
Y X Zhao Institute of Modern Physics, Lanzhou 730000, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
Z G Zhao State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Science and Technology of China, Hefei 230026, People's Republic of China
A Zhemchugov Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
B Zheng University of South China, Hengyang 421001, People's Republic of China
J P Zheng Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
W J Zheng Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
Y H Zheng University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
B Zhong Nanjing Normal University, Nanjing 210023, People's Republic of China
X Zhong Sun Yat-Sen University, Guangzhou 510275, People's Republic of China
H Zhou Shandong University, Jinan 250100, People's Republic of China
L P Zhou Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
X Zhou Wuhan University, Wuhan 430072, People's Republic of China
X K Zhou Central China Normal University, Wuhan 430079, People's Republic of China
X R Zhou State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Science and Technology of China, Hefei 230026, People's Republic of China
X Y Zhou Liaoning Normal University, Dalian 116029, People's Republic of China
Y Z Zhou Fudan University, Shanghai 200433, People's Republic of China
J Zhu Nankai University, Tianjin 300071, People's Republic of China
K Zhu Institute of High Energy Physics, Beijing 100049, People's Republic of China
K J Zhu Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
L Zhu Jilin University, Changchun 130012, People's Republic of China
L X Zhu University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
S H Zhu University of Science and Technology Liaoning, Anshan 114051, People's Republic of China
S Q Zhu Nanjing University, Nanjing 210093, People's Republic of China
T J Zhu Fudan University, Shanghai 200433, People's Republic of China
W J Zhu Fudan University, Shanghai 200433, People's Republic of China
Y C Zhu State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Science and Technology of China, Hefei 230026, People's Republic of China
Z A Zhu Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
J H Zou Institute of High Energy Physics, Beijing 100049, People's Republic of China
J Zu State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Science and Technology of China, Hefei 230026, People's Republic of China

Collapse

Human umbilical cord mesenchymal stem cell exosomes alleviate acute kidney injury by inhibiting pyroptosis in rats and NRK-52E cells

Human umbilical cord mesenchymal stem cells (hucMSCs) have been shown to improve kidney injury. Exosomes have been indicated to be important mediators of renal protection in MSC therapy. In spite of this, the mechanism remains unclear. Our study investigated how exosomes derived from hucMSCs (hucMSC-Ex) improve acute kidney injury (AKI). Exosomes were extracted by using an ultracentrifugation technique and identified by transmission electron microscopy (TEM), nanoparticle tracking analysis (NTA), and Western blot. Twenty-four male SD rats were randomly divided into four groups: sham group, sham + hucMSC-Ex group, ischemia-reperfusion injury (IRI) group, and IRI + hucMSC-Ex group. In vitro, we treated rat proximal renal tubular epithelial cell line (NRK-52E) with cisplatin to mimic in vivo models of AKI. The NRK-52E cells were treated with or without 160 μg/mL hucMSC-Ex, and 1 µg/mL cisplatin was added after 9 h. Cells were harvested after 24 h. In the IRI group, the levels of serum creatinine (Scr) and blood urea nitrogen (BUN) were increased; renal tubules were dilated, epithelial cells were vacuolated, and collagen fibers were deposited in the renal interstitium. After treatment with cisplatin, the NRK-52E cells displayed pyroptotic morphology characterized by pyroptotic bodies. The protein expression levels of fibronectin, α-smooth muscle actin (α-SMA), vimentin, gasdermin D (GSDMD), caspase-1, interleukin-1 (IL-1β) and NLRP3 in IRI tissues and in cisplatin treatment NRK-52E cells were significantly upregulated. However, after the hucMSC-Ex intervention, kidney injury was effectively improved in vivo and in vitro. The current study shows that pyroptosis is involved in AKI and that hucMSC-Ex improves AKI by inhibiting pyroptosis.

Q-TWiST analysis of survival benefits with brigatinib versus crizotinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer based on results of the ALTA-1L trial

OBJECTIVES

The ALTA-1L phase 3 open-label trial demonstrated increased progression-free survival (PFS) with brigatinib versus crizotinib in patients with anaplastic lymphoma kinase-positive (ALK-positive) locally advanced or metastatic non-small cell lung cancer (NSCLC) previously untreated with ALK-targeted therapy. This post-hoc analysis of data from the ALTA-1L trial used the quality-adjusted (QA) time without symptoms of disease or toxicity (Q-TWiST) methodology to compare the QA survival benefit of brigatinib versus crizotinib in this patient population.

PATIENTS AND METHODS

The Q-TWiST analysis was performed using final (January 29, 2021) individual patient-level blinded independent review committee (BIRC)- and investigator-assessed survival data for brigatinib (n = 137) and crizotinib (n = 138) in adult patients (N = 275) with ALK-positive locally advanced or metastatic NSCLC previously untreated with ALK-targeted therapy. Q-TWiST was compared between the two treatments. Subgroup analyses were performed in patients stratified by various clinicopathological characteristics, including presence or absence of brain metastases at baseline.

RESULTS

Brigatinib was associated with significantly longer time without symptoms of disease or toxicity (P < 0.001) than crizotinib, with significantly greater Q-TWiST (mean [SE] months: BIRC-assessed, 28.2 [1.2] versus 25.1 [1.1], P = 0.045; investigator-assessed, 28.5 [1.2] versus 24.8 [1.1], P = 0.018). Relative gains in Q-TWiST with brigatinib compared to crizotinib were clinically meaningful (BIRC-assessed, 10.4%; investigator-assessed, 12.3%). Patients with brain metastases at baseline receiving brigatinib had significantly greater Q-TWiST (mean [SE] months: BIRC-assessed, 29.0 [1.9] versus 19.0 [1.9], P = 0.0001) than those receiving crizotinib.

CONCLUSION

First-line brigatinib treatment was associated with significant and clinically meaningful gains in Q-TWiST compared to crizotinib in patients with ALK-positive locally advanced or metastatic NSCLC, supporting the results of the ALTA-1L trial and brigatinib as a safe and effective first-line treatment for ALK-positive NSCLC.

[Observation on the efficacy of different targets low-frequency repetitive transcranial magnetic stimulation for the treatment of tremor-dominant subtypes of Parkinson's disease]

Objective: To analyze the efficacy of different targets low-frequency repetitive transcranial magnetic stimulation (rTMS) for the treatment of tremor Parkinson's disease(PD). Method: A total of 82 patients with primary PD who were admitted to the Department of Neurology, Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine from April 1, 2020 to March 31, 2021 were prospectively collected. According to the clinical characteristics of major movement disorders, 82 patients with tremor type (TD) were selected to enroll.The patients were randomly divided into 3 groups at a 1∶1∶1 ratio according to the randomized coding sequence of the trial: the primary motor cortex (M1) group with 26 cases, the cerebellum group with 26 cases and the dual-site (M1, cerebellum) group with 30 cases. All patients were treated with 1 Hz low-frequency stimulation of the corresponding target once a day for 5 days a week for 2 weeks, a total of 10 times; The dosage remained unchanged during the treatment for all groups. Before and after 2 weeks' treatment, the patients were assessed with the Unified PD Rating Scale (UPDRS) and PD Quality of Life Questionnaire-39 (PDQ-39) without medication. Cortical excitability, namely transcranial magnetic stimulation motor evoked potential (TMS-MEP), [including resting motor threshold (rMT) and active motor threshold (aMT) examinations], timed up and go (TUG) and electromyographic tremor were conducted. Result: There were 82 patients, 39 males and 43 females, with an average age of (67±8) years. Before the treatment, there was no statistically significant difference in the evaluation indicators among the three groups (all P>0.05). After the treatment, the differences of the UPDRS-Ⅲ score [(38.9±2.5) vs (29.2±3.6) ], UPDRS tremor score [(23.7±2.1) vs (14.6±3.1) ], TUG time [(44.8±3.1) s vs (33.7±4.1) s], tremor amplitude [(480±126) μV vs (276±94) μV], PDQ-39 score [(51±13) vs (45±13) ], rMT [(36±17)% vs (43±13)%], and aMT [(26±16)% vs (31±12)%] were statistically significant (all P<0.01) from those before the treatment. There was no statistical difference in the above factors between the M1 group and cerebellum group (all P>0.05). There was no statistically significant difference in tremor peak frequency among the three groups before and after the treatment (all P>0.05). Conclusions: Dual-site low-frequency rTMS can improve PD tremor, while M1 or cerebellar low-frequency rTMS does not significantly improve PD tremor. Its mechanism may be to improve PD tremor symptoms by regulating cortical excitability.

HDACi-dependent Microenvironmental Normalization Overcomes Tumor Burden-induced T-cell Exhaustion

PURPOSE

T-cell exhaustion limits immunotherapy for the treatment of solid tumors. Although immune checkpoint blockade and adoptive T-cell therapy (ACT) can mediate tumor regression, their potency is often determined by tumor burden. Here, we identified tumor burden-related pathway changes that are conducive to T-cell exhaustion. We then determined whether microenvironmental reprogramming via epigenetic modulation could reverse T-cell exhaustion and improve immunotherapeutic responsiveness.

EXPERIMENTAL DESIGN

We developed a murine syngeneic tumor model wherein an increased burden ablated therapeutic responsiveness to ACT, which corresponded with systemic induction of T-cell exhaustion. Transcriptome analysis of these large tumors allowed us to characterize changes to immunosuppressive pathway expression during class I histone deacetylase inhibitor MS-275 treatment. We then measured the therapeutic impact of MS-275 during ACT and assessed T-cell exhaustion by transcriptome/phenotypic analysis.

RESULTS

ACT durably regressed small tumors but failed to control large tumors, which were associated with systemic T-cell exhaustion and ablation of T-cell responses. Large tumors were defined by an immunosuppressive pathway signature. MS-275 reversed this pathway signature and promoted durable regression of large tumors during ACT. Prototypical exhaustion marker Tim-3 was selectively upregulated in transferred T cells despite displaying a reduced exhaustion signature. Instead, we observed enhanced activation-dependent signaling correlating with enrichment of the IL2-STAT5 signaling axis. Activated CD8+ T-cell responses were predominantly skewed toward terminal effector cell-like CD44+ Tim-3hi TCF1- CD127- KLRG1+ differentiation.

CONCLUSIONS

Tumor burden-induced pathway changes can be reversed through epigenetic reprogramming, enabling the conversion from T-cell exhaustion to effector lineage differentiation.

Detection, survival, and persistence of Staphylococcus capitis NRCS-A in neonatal units in England

BACKGROUND

The multidrug-resistant Staphylococcus capitis clone, NRCS-A, is increasingly associated with late-onset sepsis in low birthweight newborns in neonatal intensive care units (NICUs) in England and globally. Understanding where this bacterium survives and persists within the NICU environment is key to developing and implementing effective control measures.

AIM

To investigate the potential for S. capitis to colonize surfaces within NICUs.

METHODS

Surface swabs were collected from four NICUs with and without known NRCS-A colonizations/infections present at the time of sampling. Samples were cultured and S. capitis isolates analysed via whole-genome sequencing. Survival of NRCS-A on plastic surfaces was assessed over time and compared to that of non-NRCS-A isolates. The bactericidal activity of commonly used chemical disinfectants against S. capitis was assessed.

FINDINGS

Of 173 surfaces sampled, 40 (21.1%) harboured S. capitis with 30 isolates (75%) being NRCS-A. Whereas S. capitis was recovered from surfaces across the NICU, the NRCS-A clone was rarely recovered from outside the immediate neonatal bedspace. Incubators and other bedside equipment were contaminated with NRCS-A regardless of clinical case detection. In the absence of cleaning, S. capitis was able to survive for three days with minimal losses in viability (<0.5 log10 reduction). Sodium troclosene and a QAC-based detergent/disinfectant reduced S. capitis to below detectable levels.

CONCLUSION

S. capitis NRCS-A can be readily recovered from the NICU environment, even in units with no recent reported clinical cases of S. capitis infection, highlighting a need for appropriate national guidance on cleaning within the neonatal care environment.

[Analysis of 7 cases of pediatric acute myeloid leukemia with DEK-NUP214 fusion gene]

Objective: To investigate the clinical features, treatment regime, and outcome of pediatric acute myeloid leukemia (AML) with DEK-NUP214 fusion gene. Methods: The clinical data, genetic and molecular results, treatment process and survival status of 7 cases of DEK-NUP214 fusion gene positive AML children admitted to the Pediatric Blood Diseases Center of Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences from May 2015 to February 2022 were analyzed retrospectively. Results: DEK-NUP214 fusion gene positive AML accounted for 1.02% (7/683) of pediatric AML diagnosed in the same period, with 4 males and 3 females. The age of disease onset was 8.2 (7.5, 9.5) years. The blast percentage in bone marrow was 0.275 (0.225, 0.480), and 6 cases were M5 by FAB classification. Pathological hematopoiesis was observed in all cases except for one whose bone marrow morphology was unknown. Three cases carried FLT3-ITD mutations, 4 cases carried NRAS mutations, and 2 cases carried KRAS mutations. After diagnosis, 4 cases received IAE induction regimen (idarubicin, cytarabine and etoposide), 1 case received MAE induction regimen (mitoxantrone, cytarabine and etoposide), 1 case received DAH induction regimen (daunorubicin, cytarabine and homoharringtonine) and 1 case received DAE induction regimen (daunorubicin, cytarabine and etoposide). Complete remission was achieved in 3 cases after one course of induction. Four cases who did not achieved complete remission received CAG (aclarubicin, cytarabine and granulocyte colony-stimulating factor), IAH (idarubicin, cytarabine and homoharringtonine), CAG combined with cladribine, and HAG (homoharringtonine, cytarabine and granulocyte colony-stimulating factor) combined with cladribine reinduction therapy, respectively, all 4 cases reached complete remission. Six patients received hematopoietic stem cell transplantation (HSCT) after 1-2 sessions of intensive consolidation treatment, except that one case was lost to follow-up after complete remission. The time from diagnosis to HSCT was 143 (121, 174) days. Before HSCT, one case was positive for flow cytometry minimal residual disease and 3 cases were positive for DEK-NUP214 fusion gene. Three cases accepted haploid donors, 2 cases accepted unrelated cord blood donors, and 1 case accepted matched sibling donor. The follow-up time was 20.4 (12.9, 53.1) months, the overall survival and event free survival rates were all 100%. Conclusions: Pediatric AML with DEK-NUP214 fusion gene is a unique and rare subtype, often diagnosed in relatively older children. The disease is characterized with a low blast percentage in bone marrow, significant pathological hematopoiesis and a high mutation rate in FLT3-ITD and RAS genes. Low remission rate by chemotherapy only and very high recurrence rate indicate its high malignancy and poor prognosis. Early HSCT after the first complete remission can improve its prognosis.

Oncolytic BHV-1 Is Sufficient to Induce Immunogenic Cell Death and Synergizes with Low-Dose Chemotherapy to Dampen Immunosuppressive T Regulatory Cells

Immunogenic cell death (ICD) can switch immunologically "cold" tumors "hot", making them sensitive to immune checkpoint inhibitor (ICI) therapy. Many therapeutic platforms combine multiple modalities such as oncolytic viruses (OVs) and low-dose chemotherapy to induce ICD and improve prognostic outcomes. We previously detailed many unique properties of oncolytic bovine herpesvirus type 1 (oBHV) that suggest widespread clinical utility. Here, we show for the first time, the ability of oBHV monotherapy to induce bona fide ICD and tumor-specific activation of circulating CD8⁺ T cells in a syngeneic murine model of melanoma. The addition of low-dose mitomycin C (MMC) was necessary to fully synergize with ICI through early recruitment of CD8⁺ T cells and reduced infiltration of highly suppressive PD-1⁺ Tregs. Cytokine and gene expression analyses within treated tumors suggest that the addition of MMC to oBHV therapy shifts the immune response from predominantly anti-viral, as evidenced by a high level of interferon-stimulated genes, to one that stimulates myeloid cells, antigen presentation and adaptive processes. Collectively, these data provide mechanistic insights into how oBHV-mediated therapy modalities overcome immune suppressive tumor microenvironments to enable the efficacy of ICI therapy.

Epigenetic modification of CSDE1 locus dictates immune recognition of nascent tumorigenic cells

Weak immunogenicity of tumor cells is a root cause for the ultimate failure of immunosurveillance and immunotherapy. Although tumor evolution can be shaped by immunoediting toward a less immunogenic phenotype, mechanisms governing the initial immunogenicity of primordial tumor cells or original cancer stem cells remain obscure. Here, using a single tumor-repopulating cell (TRC) to form tumors in immunodeficient or immunocompetent mice, we demonstrated that immunogenic heterogeneity is an inherent trait of tumorigenic cells defined by the activation status of signal transducer and activator of transcription 1 (STAT1) protein in the absence of immune pressure. Subsequent investigation identified that the RNA binding protein cold shock domain-containing protein E1 (CSDE1) can promote STAT1 dephosphorylation by stabilizing T cell protein tyrosine phosphatase (TCPTP). A methyltransferase SET and MYN domain-containing 3 (SMYD3) was further identified to mediate H3K4 trimethylation of CSDE1 locus, which was under the regulation of mechanotransduction by cell-matrix and cell-cell contacts. Thus, owing to the differential epigenetic modification and subsequent differential expression of CSDE1, nascent tumorigenic cells may exhibit either a high or low immunogenicity. This identified SMYD3-CSDE1 pathway represents a potential prognostic marker for cancer immunotherapy effectiveness that requires further investigation.

Short- and long-term outcomes of laparoscopic versus open pelvic exenteration for locally advanced rectal cancer: a single-center propensity score matching analysis

BACKGROUND

Research on short-term outcomes and long-term oncological results of laparoscopic pelvic exenteration (LPE) for locally advanced rectal cancer (LARC) is still limited. The purpose of this study was to compare the outcomes of LPE and open pelvic exenteration (OPE).

METHODS

Between January 2010 and December 2019, consecutive LARC patients who underwent radical pelvic exenteration at Peking University First Hospital were enrolled. Groups were matched at a 1:1 ratio using propensity score matching. The primary endpoints were 3 year overall survival (OS) and disease-free survival (DFS). The secondary endpoints were postoperative short-term outcomes.

RESULTS

There were 144 patients (68 males and 76 females, median age 58.5 [range 27.0-86.0] years). After matching, patients were stratified into LPE (n = 48) and OPE (n = 48) groups (LPE: 24 males and 24 females, median age 57.0 [range 27.0-81.0] years; OPE: 26 males and 22 females, median age 58.0[range 36.0-80.0] years). There were no significant differences on baseline data between the two groups. Compared with the OPE group, the LPE group had a significantly lower estimated blood loss (200 vs 500 ml, p = 0.003), less overall postoperative complications (12/48 vs 25/48, p = 0.006), less surgical site infection (8/48 vs 20/48, p = 0.007), shorter length of stay (12 vs. 15 days, p = 0.005), but similar operative time (344 vs. 360 min, p = 0.493). The pathological R0 resection rate (98.0% vs. 93.7%, p = 0.610), 3 year local recurrence (18.4% vs. 23.5, p = 0.140), 3 year OS (74.6% vs. 65.5%, p = 0.290) and 3-year DFS (60.0% vs. 50.3%, p = 0.208) were similar between the two groups. Shorter distance from anal verge (HR = 0.92, p = 0.042), (y) pT4b (HR = 2.45, p = 0.023), (y)pN1-2 (HR = 2.42, p = 0.004) and positive CRM (HR = 6.23, p = 0.004) were independent prognostic risks for 3 year DFS.

CONCLUSIONS

LPE can be performed safely and has certain short-term advantages over OPE, most notably less blood loss and surgical site infection. However, LPE does not improve long-term oncological outcomes.

[Effects of mechanical tension on the formation of hypertrophic scars in rabbit ears and transforming growth factor-β1/Smad signaling pathway]

Objective: To explore the effects of mechanical tension on the formation of hypertrophic scars in rabbit ears and transforming growth factor-β1 (TGF-β1)/Smad signaling pathway. Methods: The experimental research method was adopted. Six New Zealand white rabbits, male or female, aged 3-5 months were used and 5 full-thickness skin defect wounds were made on the ventral surface of each rabbit ear. The appearance of all rabbit ear wounds was observed on post surgery day (PSD) 0 (immediately), 7, 14, 21, and 28. On PSD 28, the scar formation rate was calculated. Three mature scars in the left ear of each rabbit were included in tension group and the arch was continuously expanded with a spiral expander. Three mature scars in the right ear of each rabbit were included in sham tension group and only the spiral expander was sutured without expansion. There were 18 scars in each group. After mechanical tension treatment (hereinafter referred to as treatment) for 40 days, the color and texture of scar tissue in the two groups were observed. On treatment day 40, the scar elevation index (SEI) was observed and calculated; the histology was observed after hematoxylin eosin staining, and the collagen morphology was observed after Masson staining; mRNA expressions of TGF-β1, Smad3, collagen Ⅰ, collagen Ⅲ, and α-smooth muscle actin (α-SMA) in scar tissue were detected by real-time fluorescence quantitative reverse transcription polymerase chain reaction; and the protein expressions of TGF-β1, collagen Ⅰ, collagen Ⅲ, and α-SMA, and phosphorylation level of Smad3 in scar tissue were detected by Western blotting. The number of samples of each group in the experiments was 3. Data were statistically analyzed with independent sample t test. Results: On PSD 0, 5 fresh wounds were formed on all the rabbit ears; on PSD 7, the wounds were scabbed; on PSD 14, most of the wounds were epithelialized; on PSD 21, all the wounds were epithelialized; on PSD 28, obvious hypertrophic scars were formed. The scar formation rate was 75% (45/60) on PSD 28. On treatment day 40, the scar tissue of rabbit ears in tension group was more prominent than that in sham tension group, the scar tissue was harder and the color was more ruddy; the SEI of the scar tissue of rabbit ears in tension group (2.02±0.08) was significantly higher than 1.70±0.08 in sham tension group (t=5.07, P<0.01). On treatment day 40, compared with those in sham tension group, the stratum corneum of scar tissue became thicker, and a large number of new capillaries, inflammatory cells, and fibroblasts were observed in the dermis, and collagen was more disordered, with nodular or swirling distribution in the scar tissue of rabbit ears in tension group. On treatment day 40, the mRNA expressions of TGF-β1, Smad3, collagen Ⅰ, collagen Ⅲ, and α-SMA in the scar tissue of rabbit ears in tension group were respectively 1.81±0.25, 5.71±0.82, 7.86±0.56, 4.35±0.28, and 5.89±0.47, which were significantly higher than 1.00±0.08, 1.00±0.12, 1.00±0.13, 1.00±0.14, and 1.00±0.14 in sham tension group (with t values of 5.36, 9.82, 20.60, 18.26, and 17.13, respectively, all P<0.01); the protein expressions of TGF-β1, collagen Ⅰ, collagen Ⅲ, and α-SMA, and phosphorylation level of Smad3 in the scar tissue of rabbit ears in tension group were respectively 0.865±0.050, 0.895±0.042, 0.972±0.027, 1.012±0.057, and 0.968±0.087, which were significantly higher than 0.657±0.050, 0.271±0.029, 0.631±0.027, 0.418±0.023, and 0.511±0.035 in sham tension group (with t values of 5.08, 21.27, 15.55, 16.70, and 8.40, respectively, all P<0.01). Conclusions: Mechanical tension can inhibit the regression of hypertrophic scars in rabbit ears through stimulating the hyperplasia of scars, inhibiting the normal arrangement of dermal collagen fibers, and intensifying the deposition of collagen fibers, and the mechanism may be related to the activation of TGF-β1/Smad signaling pathway by mechanical tension.

Comparison of suspected and confirmed internal EVD-related infections: a prospective multi-centre U.K. observational study

Background

Diagnosis of internal external ventricular drain (EVD)-related infections (iERI) is an area of diagnostic difficulty. Empiric treatment is often initiated on clinical suspicion. There is limited guidance around antimicrobial management of confirmed versus suspected iERI.

Methods

Data on patients requiring EVD insertion were collected from 21 neurosurgical units in the United Kingdom from 2014 to 2015. Confirmed iERI was defined as clinical suspicion of infection with positive cerebrospinal fluid (CSF) culture and/or Gram stain. Cerebrospinal fluid, blood, and clinical parameters and antimicrobial management were compared between the 2 groups. Mortality and Modified Rankin Scores were compared at 30 days post-EVD insertion.

Results

Internal EVD-related infection was suspected after 46 of 495 EVD insertions (9.3%), more common after an emergency insertion. Twenty-six of 46 were confirmed iERIs, mostly due to Staphylococci (16 of 26). When confirmed and suspected infections were compared, there were no differences in CSF white cell counts or glucose concentrations, nor peripheral blood white cell counts or C-reactive protein concentrations. The incidence of fever, meningism, and seizures was also similar, although altered consciousness was more common in people with confirmed iERI. Broad-spectrum antimicrobial usage was prevalent in both groups with no difference in median duration of therapy (10 days [interquartile range {IQR}, 7–24.5] for confirmed cases and 9.5 days [IQR, 5.75–14] for suspected, P = 0.3). Despite comparable baseline characteristics, suspected iERI was associated with lower mortality and better neurological outcomes.

Conclusions

Suspected iERI could represent sterile inflammation or lower bacterial load leading to false-negative cultures. There is a need for improved microbiology diagnostics and biomarkers of bacterial infection to permit accurate discrimination and improve antimicrobial stewardship.

P11.24.A The anisotropic component of the decomposed diffusion tensor predicts overall survival in patients with glioblastoma

Background

The diffusion tensor can be decomposed into isotropic (DTI-p) and anisotropic (DTI-q) components (Peña et al., 2006). Regions of DTI-q abnormality have a high tumour burden and increased surgical resection of abnormal DTI-q positively correlates with overall survival (OS) (Yan et al., 2017). We aimed to establish if median voxel DTI-q (MVQ) or a distribution measure of DTI-q (DMQ) could act as a neuro-imaging biomarker, to predict OS in patients with glioblastoma.

Material and Methods

Diffusion tensor decomposition was used to create DTI-p and DTI-q maps, using FSL software (FMRIB Software Library, Oxford). MVQ and DMQ (the 95th centile minus the 5th centile of the DTI-q distribution, divided by the MVQ) were calculated from the preoperative whole brain (WB), contrast-enhancing (CE), and non-contrast-enhancing (NCE) hemisphere DTI-q maps, using fslstats, for 33 patients with glioblastoma. Using R Studio, multiple linear regression (MLR) models were computed to establish if MVQ or DMQ of the WB, CE and NCE hemispheres or age, significantly predicts OS. The Breusch-Pagan Test, on package “lmtest” in R, was calculated for all MLR models, to determine if heteroscedasticity was present and, if so, bootstrapped multiple regression (BMR) models were computed using package “boot” in R.

Results

Evidence for heteroscedasticity was present in MLRs that modelled the relationship between DMQ of WB, age, and OS (BP = 6.032, p = 0.014) and DMQ of CE hemisphere, age, and OS (BP = 7.163, p = 0.028). In the BMR of WB DMQ, age, and OS, the 95% bias-corrected accelerated confidence intervals (BCa-CI) for the WB DMQ regression coefficient was 133.5 - 1851.4 and included the WB DMQ estimated coefficient of 803.9. The BMR of CE hemisphere DMQ, age, and OS, computed a 95% BCa-CI for the CE hemisphere DMQ coefficient of 101.8 - 1579.6, containing the CE hemisphere DMQ coefficient estimate of 612.414. For both BMRs, the 95% BCa-CI for age coefficients crossed a value of 0. From computed MLR models, WB MVQ (t = -2.569, p = 0.015), CE hemisphere MVQ (t = -2.143, p = 0.040), NCE hemisphere MVQ (t = -2.567, p = 0.015) and NCE hemisphere DMQ (t = 2.39, p = 0.024) were significant predictors of OS. Age did not significantly predict OS in any models and was not significantly related to WB, CE and NCE hemisphere MVQ or DMQ.

Conclusion

WB, CE and NCE hemisphere MVQ and DMQ predict OS in our tested subgroup of patients with glioblastoma. Age is not a significant predictor of OS and does not significantly correlate with MVQ or DMQ. The median value and distribution spread of DTI-q may act as a prognostic biomarker in glioblastoma, facilitating patient stratification.

P15.07.A Predicting sites of local tumour progression - what should be our imaging biomarker?

Background

Glioblastoma is the most aggressive primary brain tumour diagnosed in adults. Despite intensive treatment of maximal safe resection and chemoradiotherapy, the prognosis remains grim due to invasive tumour cells. Current treatment and standard imaging methods are highly limited in terms of managing these invasive cells as they are often located outside the area of surgical resection and are generally resistant to chemoradiation. DTI appears to be a promising tool for imaging tumour cell invasion and predicting the site of recurrence especially when decomposed into its anisotropic (q) and isotropic (p) components. The aim of this study is to investigate the sensitivity of imaging biomarkers as predictors of recurrence.

Material and Methods

All pre-op and recurrence sequences were co-registered to the pre-op post-contrast T1-weighted images as reference. Co-registration of images was performed using FSL and ANTs. The ROIs for 49 patients with a primary diagnosis of GBM were segmented using 3DSlicer. Each voxel was assigned to one of four status: true negative, false negative, true positive and false positive. Sensitivity and specificity between the pre-op ROIs and the progression region were calculated using FSL. The significance of the differences in sensitivity and specificity between the ROIs was computed in MATLAB.

Results

The sensitivity for the contrast enhancing region was 48.77 ± 26.13 (Mean ± SD) and 62.40 ± 23.07 (Mean ± SD). The abnormal q alone has a significantly greater sensitivity than the contrast enhancing region (t = -2.7327, df = 96, p-value = 0.0075). The sensitivity for the ROI of combined contrast enhancement and abnormal q was 65.86 ± 23.29 (Mean ± SD). There is an even more significant increase in sensitivity when the contrast enhancing ROI is combined with abnormal q region (t = -3.4133, df = 96, p-value = 9.4123e-04) compared to when it is alone. There was no statistical difference in the specificities of the different ROIs.

Conclusion

Current surgical and radiation volumes focus solely on pre-op contrast enhancement. However, these results suggest that combining the abnormal q with the standard contrast enhancing region is a more sensitive predictor of tumour recurrence than contrast enhancement alone, while still retaining high specificity. The higher sensitivity is an indicator of correct identification of tumour recurrence while the high specificity correctly identifies normal brain, or non-recurrent regions. These results are currently being prospectively assessed in a multi-centre study (PRaM-GBM).

HDACi promotes inflammatory remodeling of the tumor microenvironment to enhance epitope spreading and antitumor immunity

Adoptive cell therapy (ACT) with tumor-specific memory T cells has shown increasing efficacy in regressing solid tumors. However, tumor antigen heterogeneity represents a longitudinal challenge for durable clinical responses due to the therapeutic selective pressure for immune escape variants. Here, we demonstrated that delivery of the class I histone deacetylase inhibitor MS-275 promoted sustained tumor regression by synergizing with ACT in a coordinated manner to enhance cellular apoptosis. We found that MS-275 altered the tumor inflammatory landscape to support antitumor immunoactivation through the recruitment and maturation of cross-presenting CD103⁺ and CD8⁺ DCs and depletion of Tregs. Activated endogenous CD8⁺ T cell responses against nontarget tumor antigens were critically required for the prevention of tumor recurrence. Importantly, MS-275 altered the immunodominance hierarchy by directing epitope spreading toward the endogenous retroviral tumor–associated antigen p15E. Our data suggest that MS-275 in combination with ACT multimechanistically enhanced epitope spreading and promoted long-term clearance of solid tumors.

IFNAR blockade synergizes with oncolytic VSV to prevent virus-mediated PD-L1 expression and promote antitumor T cell activity

Oncolytic virotherapies have shown excellent promise in a variety of cancers by promoting antitumor immunity. However, the effects of oncolytic virus-mediated type I interferon (IFN-I) production on antitumor immunity remain unclear. Recent reports have highlighted immunosuppressive functions of IFN-I in the context of checkpoint inhibitor and cell-based therapies. In this study, we demonstrate that oncolytic virus-induced IFN-I promotes the expression of PD-L1 in tumor cells and leukocytes in a IFN receptor (IFNAR)-dependent manner. Inhibition of IFN-I signaling using a monoclonal IFNAR antibody decreased IFN-I-induced PD-L1 expression and promoted tumor-specific T cell effector responses when combined with oncolytic virotherapy. Furthermore, IFNAR blockade improved therapeutic response to oncolytic virotherapy in a manner comparable with PD-L1 blockade. Our study highlights a critical immunosuppressive role of IFN-I on antitumor immunity and uses a combination strategy that improves the response to oncolytic virotherapy.

Cost-effectiveness analyses of denosumab for osteoporosis: a systematic review

This paper systematically reviewed and assessed all retrievable pharmacoeconomic studies on denosumab for the treatment of osteoporosis. Denosumab was more cost-effective in patients with older age, prior fracture experience, lower BMD T-scores, and more risk factors. ESCEO-IOF guidelines were more applicable to improve the quality of pharmacoeconomic studies in osteoporosis.

INTRODUCTION

There are many pharmacoeconomic studies on denosumab for osteoporosis. However, the corresponding reviews are outdated or incomplete and need to be updated and refined. This article aims to systematically review and evaluate all retrievable pharmacoeconomic studies of denosumab for osteoporosis.

METHODS

A systematic literature search was performed utilizing PubMed, EMBASE(Ovid), Proquest(EconLit), Chongqing VIP, WanFang Database, and Chinese National Knowledge Infrastructure to identify full-text articles published before September 2021. The quality of full-text articles was evaluated by the Consolidated Health Economic Evaluation Reporting Standards(CHEERS) and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases International Osteoporosis Foundation guideline(ESCEO-IOF).

RESULTS

In total, 21 full-text articles were eligible for inclusion. Denosumab for postmenopausal osteoporosis was not dominant compared to zoledronate and teriparatide. However, denosumab was dominant compared with strontium ranelate, raloxifene, and ibandronate in patients over 65 years. The probabilities of denosumab being cost-effective or dominant were more than 85% compared with no treatment and risedronate in patients aged over 70 years. Compared to alendronate, the highest rate of denosumab dominance occurred in patients aged 65 to 75 years, at about 65%. Most of the articles had higher CHEERS scores than ESCEO-IOF scores (converted into percentages).

CONCLUSIONS

The cost-effectiveness of denosumab for the treatment of osteoporosis was influenced by multiple factors. Generally, denosumab was more cost-effective in patients with older age, prior fracture experience, lower BMD T-scores, and more risk factors. ESCEO-IOF guidelines were more applicable to improve the transparency, generalization, and quality of pharmacoeconomic studies in osteoporosis.

[Preliminary experience of surgical treatment for torus tubarius hypertrophy in children]

Objective: To assess the incidence of symptomatic torus tubarius hypertrophy (TTH) in recurred OSA in children, and to explore the preliminary experience of partial resection of TTH assisted with radiofrequency ablation. Methods: From January 2004 to February 2020, 4 922 children, who diagnosed as OSA and received adenotonsillectomy at the Department of Otolaryngology, The 4th Medical Center of the PLA General Hospital, were retrospectively reviewed. There were 3 266 males and 1 656 females, the age ranged from 1 to 14 years old(median age of 5.0 years). Twenty-two cases were identified with recurrence of OSA syndrome, and the clinical data, including sex, age of primary operation, age of recurrence and presentation, and opertation methods were analyzed. Follow-up was carried out by outpatient visit or telephone. Graphpad prism 5.0 software was used for statistical analysis. Results: Twenty-two cases were identified as recurred OSA and received revised surgery in 4 922 cases. Among these 22 cases, 11 cases were diagnosed as TTH resulting in an incidence of 2.23‰(11/4 922), 1 case was cicatricial adhesion on tubal torus (0.20‰, 1/4 922), 10 cases were residual adenoid combined with tubal tonsil hypertrophy (2.03‰, 10/4 922). Median age of primary operation was 3.0 years (range:2.4 to 6.0 years) in 11 TTH cases. Recurrent interval varied from 2 months to 5.5 years (2.4±1.9 years) after first operation. Age of revised partial resection of TTH was 7.0±2.7 years (range: 4.0 to 12.0 years). Average time interval between primary operation and revised operation was 3.5±2.1 years (range: 0.5 to 6.0 years). Individualized treatments were carried out based on partial resection of TTH assisted with radiofrequency ablation. All of 11 cases received satisfied therapeutic results without nasopharyngeal stenosis occured. Twenty-two cases were followed up for 1.6 to 13 years (median follow-up time was 6.2 years). Conclusions: TTH contributed to recurred OSA in child. TTH might be misdiagnosed as tubal tonsil hypertrophy. Partial resection of TTH assisted with radiofrequency ablation was a safty and effective treatment.

Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2

The emerging SARS-CoV-2 variants of concern (VOCs) threaten the effectiveness of current COVID-19 vaccines administered intramuscularly and designed to only target the spike protein. There is a pressing need to develop next-generation vaccine strategies for broader and long-lasting protection. Using adenoviral vectors (Ad) of human and chimpanzee origin, we evaluated Ad-vectored trivalent COVID-19 vaccines expressing spike-1, nucleocapsid, and RdRp antigens in murine models. We show that single-dose intranasal immunization, particularly with chimpanzee Ad-vectored vaccine, is superior to intramuscular immunization in induction of the tripartite protective immunity consisting of local and systemic antibody responses, mucosal tissue-resident memory T cells and mucosal trained innate immunity. We further show that intranasal immunization provides protection against both the ancestral SARS-CoV-2 and two VOC, B.1.1.7 and B.1.351. Our findings indicate that respiratory mucosal delivery of Ad-vectored multivalent vaccine represents an effective next-generation COVID-19 vaccine strategy to induce all-around mucosal immunity against current and future VOC.

[The clinical efficacy of the stratification medical treatment based on the risk estimation of motor complications in Parkinson's disease]

Objectives: To evaluate the clinical efficacy of the stratification medical treatment based on the motor complications risk estimation in improving the quality of life, motor symptoms and delaying the motor complications in Parkinson's patients. Methods: Outpatients and inpatients from Xinhua Hospital, Shanghai Jiao Tong University, were recruited between November 2019 and June 2020. The participants were all clinically diagnosed with PD and treated with anti-PD medications, but had no history of motor complications, with the 8-item Parkinson's disease questionnaire summary index (PDQ-8 SI)>18.59. At baseline, the demographic characteristics, PD medical history, levodopa dosage (LD) and levodopa equivalent dosage (LED) were collected, and the evaluation of PDQ-8, Unified Parkinson's disease rating scale (UPDRS)-Ⅱ and Ⅲ, Hoehn and Yahr (H&Y) grade, Hamilton anxiety scale-14 (HAMA-14), Hamilton depression scale-24 (HAMD-24), mini-mental state examination (MMSE), Pittsburgh sleep quality index (PSQI), and Epworth sleepiness scale (ESS) tools was accomplished in all participants. Meanwhile, a Parkinson's disease risk estimation scale for motor complications was used to assess patients' risk of motor complications, and thus the medication was stratified in PD patients accordingly. During the 6-month and 12-month follow-ups, the evaluation of the above-mentioned parameters was repeated in all participants. At the 3-month and 9-month follow-ups, the information of anti-PD medications, the occurrence of motor complications (motor fluctuations and dyskinesia) and adverse drug reactions were recorded, and PDQ-8 was also evaluated. Results: Two hundred and fifty-one patients completed the 1-year follow-up, with 135 males and 116 females. At baseline, the median age of the patients was 66 (60, 71) years and the median PDQ-8 SI was 31.2 (21.9, 40.6). Additionally, 15.9% (40/251) of the patients were at high risk of motor fluctuation, and 7.2% (18/251) were at high risk of dyskinesia. There were significant differences in the age of onset, disease duration, PD treatment duration, the scores of UPDRS-Ⅱ and Ⅲ, H&Y Grade, and PDQ-8 SI among PD patients of different risk groups (all P<0.05). In the 12th month, the median of PDQ-8 SI, Δ PDQ-8 SI and Δ UPDRS-Ⅲ was 12.5 (9.4, 18.8), -15.6 (-21.9, -9.4) and -9(-16, -4), respectively, which was statistically different from that of baseline (all P<0.05). The change of UPDRS-Ⅱ scores in the group with high risk of motor fluctuation was statistically different from that in the groups with low and moderate risk (P<0.05). The changes of PSQI score, LD and LED in the group with high risk of dyskinesia was statistically different from those in the groups with low and moderate risk (all P<0.05). During the follow-up, the incidence of motor fluctuation and dyskinesia was 9.56% (24/251) and 5.97% (15/251), respectively. Conclusion: The stratification medical treatment might have a positive intervention effect on promoting a better quality of life, improving motor symptoms and delaying motor complications in PD patients.

A Combination of Chemotherapy and Oncolytic Virotherapy Sensitizes Colorectal Adenocarcinoma to Immune Checkpoint Inhibitors in a cDC1-Dependent Manner

Immune checkpoint therapy has shown great promise in the treatment of cancers with a high mutational burden, such as mismatch repair-deficient colorectal carcinoma (dMMR CRC). However, many patients fail to respond to immune checkpoint therapy. Using a mouse model of dMMR CRC, we demonstrated that tumors can be further sensitized to immune checkpoint therapy by using a combination of low-dose chemotherapy and oncolytic HSV-1. This combination induced the infiltration of CD8+ and CD4+ T cells into the tumor and the upregulation of gene signatures associated with the chemoattraction of myeloid cell subsets. When combined with immune checkpoint therapy, the combination promoted the infiltration of activated type 1 conventional dendritic cells (cDC1s) into the tumor. Furthermore, we found this combination strategy to be dependent on cDC1s, and its therapeutic efficacy to be abrogated in cDC1-deficient Batf3-/- mice. Thus, we demonstrated that the adjuvanticity of dMMR CRCs can be improved by combining low-dose chemotherapy and oncolytic HSV-1 in a cDC1-dependent manner.

Response to FEC Chemotherapy and Oncolytic HSV-1 Is Associated with Macrophage Polarization and Increased Expression of S100A8/A9 in Triple Negative Breast Cancer

Simple Summary

We have previously reported that a combination of clinical chemotherapies and oncolytic HSV-1 works to sensitize tumors to respond to immune checkpoint blockade. We further showed that this therapeutic platform worked via the upregulation of B cells and the concomitant control of immunosuppressive myeloid cells. In this manuscript, we sought to further dissect the mechanism of myeloid cell regulation and differentiation and to identify a therapeutically driven gene signature that is associated with the switch in the myeloid phenotype. This work not only impacts triple-negative breast cancer but all solid tumor phenotypes as we aim to better understand the underlying immunology associated with responses to immune checkpoint therapies in these typically refractory disease types.

Abstract

The era of immunotherapy has seen an insurgence of novel therapies driving oncologic research and the clinical management of the disease. We have previously reported that a combination of chemotherapy (FEC) and oncolytic virotherapy (oHSV-1) can be used to sensitize otherwise non-responsive tumors to immune checkpoint blockade and that tumor-infiltrating B cells are required for the efficacy of our therapeutic regimen in a murine model of triple-negative breast cancer. In the studies herein, we have performed gene expression profiling using microarray analyses and have investigated the differential gene expression between tumors treated with FEC + oHSV-1 versus untreated tumors. In this work, we uncovered a therapeutically driven switch of the myeloid phenotype and a gene signature driving increased tumor cell killing.

Fate and transport in environmental quality

Changes in pollutant concentrations in environmental media occur both from pollutant transport in water or air and from local processes, such as adsorption, degradation, precipitation, straining, and so on. The terms "fate and transport" and "transport and fate" reflect the coupling of moving with the carrier media and biogeochemical processes describing local transformations or interactions. The Journal of Environmental Quality (JEQ) was one of the first to publish papers on fate and transport (F&T). This paper is a minireview written to commemorate the 50th anniversary of JEQ and show how the research interests, methodology, and public attention have been reflected in fate and transport publications in JEQ during the last 40 years. We report the statistics showing how the representation of different pollutant groups in papers changed with time. Major focus areas have included the effect of solution composition on F&T and concurrent F&T, the role of organic matter, and the relative role of different F&T pathways. The role of temporal and spatial heterogeneity has been studied at different scales. The value of long-term F&T studies and developments in modeling as the F&T research approach was amply demonstrated. Fate and transport studies have been an essential part of conservation measure evaluation and comparison and ecological risk assessment. For 50 years, JEQ has delivered new insights, methods, and applications related to F&T science. The importance of its service to society is recognized, and we look forward to new generations of F&T researchers presenting their contributions in JEQ.

Combination therapy with interleukin-15 and metformin as a synergistic treatment for pancreatic cancer

OBJECTIVE

To investigate the efficacies and mechanisms of combination therapy with interleukin-15 (IL-15) and metformin (Met) on suppressing pancreatic cell proliferation and protecting Panc02-bearing mice.

MATERIALS AND METHODS

MTT assays were applied to assess the inhibitory effects of IL-15 combined Met or Met and IL-15 alone on proliferation of normal HPDE6-C7 and Panc02 cells. After tumor grew up to 150 mm3, the Panc02-bearing xenograft model mice were randomly divided into saline group, IL-15 and Met alone group and combined treatment group (n=8) with the administration of each agent every other day for three weeks, and survival rates were recorded. The changes in tumor size, expression levels of the apoptosis, autophagy as well as Akt/mTOR/STAT3-related factors in tumor tissues were all measured.

RESULTS

MTT assays demonstrated significantly inhibiting efficacy of combination therapy with IL-15 and Met on Panc02 cell proliferation compared to other groups (all p<0.05) with combination index<1 showing evident synergistic effect. Moreover, the apoptosis rate of Panc02 cell under combined treatment were 95.5±3.2% and significantly higher than those of others (all p<0.01). In addition, combined administration remarkably inhibited the growth of pancreatic carcinoma, and improved survival rate of Panc02-bearing model with less body weight loss. Furthermore, combined treatment significantly downregulated anti-apoptotic proteins as well as Akt/mTOR/STAT3 signaling pathway and upregulated autophagy related factors, respectively, compared with those of monotherapy groups in both Panc02 cells and tumor tissues.

CONCLUSIONS

Combined treatment of IL-15 with Met showed synergistic anti-tumor efficacies on Panc02 cells attributing to promotion on apoptosis, autophagy and inhibition on Akt/mTOR/STAT3 signaling-transduction in Panc02-bearing model mice.

The association of metabolic health obesity with incidence of carotid artery plaque in Chinese adults

BACKGROUND AND AIMS

We aimed to evaluate the association between different obese phenotypes with carotid artery plaque (CAP) event.

METHOD AND RESULTS

The current retrospective cohort study was performed in 32,778 Chinese adults (19,221 men and 13,557 women, aged 41.9 ± 11.0 years). Obese phenotypes were assessed based on baseline body mass index (<24.0 vs. ≥24.0 kg/m²) and metabolic characteristics (health vs. unhealth). All the participants were further classified into four groups: metabolic health and normal weight (MHNW), metabolic unhealth and normal weight (MUHNW), metabolic health and overweight (MHO), and metabolic unhealth and overweight (MUHO). Ultrasound B-mode imaging was annually performed to evaluate CAP throughout the study. We have identified 2142 CAP cases during 5-year follow-up. Comparing with the MHNW group, the hazard ratios for the risk of incident CAP was 2.44 (95% CI:1.92 and 3.09) for the MUHNW group, 1.52 (95% CI:1.06 and 2.18) for the MHO group, and 1.8 (95% CI:1.4 and 2.33) for the MUHO group. The association was more pronounced in young adults (<65 y) than that in aged adults (≥65 y). Sensitivity analysis generated similar results with the main analysis.

CONCLUSION

MUHNW, MHO, and MUHO were associated with the risk of CAP.

Immune checkpoint blockade in triple negative breast cancer influenced by B cells through myeloid-derived suppressor cells

Triple negative breast cancer holds a dismal clinical outcome and as such, patients routinely undergo aggressive, highly toxic treatment regimens. Clinical trials for TNBC employing immune checkpoint blockade in combination with chemotherapy show modest prognostic benefit, but the percentage of patients that respond to treatment is low, and patients often succumb to relapsed disease. Here, we show that a combination immunotherapy platform utilizing low dose chemotherapy (FEC) combined with oncolytic virotherapy (oHSV-1) increases tumor-infiltrating lymphocytes, in otherwise immune-bare tumors, allowing 60% of mice to achieve durable tumor regression when treated with immune checkpoint blockade. Whole-tumor RNA sequencing of mice treated with FEC + oHSV-1 shows an upregulation of B cell receptor signaling pathways and depletion of B cells prior to the start of treatment in mice results in complete loss of therapeutic efficacy and expansion of myeloid-derived suppressor cells. Additionally, RNA sequencing data shows that FEC + oHSV-1 suppresses genes associated with myeloid-derived suppressor cells, a key population of cells that drive immune escape and mediate therapeutic resistance. These findings highlight the importance of tumor-infiltrating B cells as drivers of antitumor immunity and their potential role in the regulation of myeloid-derived suppressor cells.

Functional Analysis of Tumor-Infiltrating Myeloid Cells by Flow Cytometry and Adoptive Transfer

The tumor-infiltrating myeloid cell compartment represents a heterogeneous population of broadly immunosuppressive cells that have been exploited by the tumor to support its growth. Their accumulation in tumor and secondary lymphoid tissue leads to the suppression of antitumor immune responses and is thus a target for therapeutic intervention. As it is known that the local cytokine milieu can dictate the functional programming of tumor-infiltrating myeloid cells, strategies have been devised to manipulate the tumor microenvironment (TME) to express a cytokine landscape more conducive to antitumor myeloid cell activity. To evaluate therapy-induced changes in tumor-infiltrating myeloid cells, this paper will outline the procedure to dissociate intradermal/subcutaneous tumor tissue from solid tumor-bearing mice in preparation for leukocyte recovery. Strategies for flow cytometric analysis will be provided to enable the identification of heterogeneous myeloid populations within isolated leukocytes and the characterization of unique myeloid phenotypes. Lastly, this paper will describe a means of purifying viable myeloid cells for functional assays and determining their therapeutic value in the context of adoptive transfer.

Effectiveness assessment of improvement measures in physical protection system monitoring center

The optimization measures in the physical protection system monitoring center of a nuclear power plant include the prioritization of alarm signals, optimization of sound and light alarm form, improvement of the layout of video monitor screen, security training, and strengthening of organizational management. Based on the fuzzy analytic hierarchy process, the influence of these factors on the probability of alert assessment and guard’s respond time in the EASI method are quantitatively analyzed. Making full use of the measures for prioritization of alarm signals can effectively promote the improvement of human-computer interaction efficiency. The degree of influence of the four factors (guarder’s status, decision strategy, guarder’s training and organization management) on guard’s decision-making is roughly the same.

The synergistic antifungal activity of resveratrol with azoles against Candida albicans

Candida albicans is one of the most common clinical pathogenic microorganisms and it is becoming a serious health threat, particularly to immunocompromised populations. Drug resistance of Candida species has also frequently emerged, and combination therapy for fungal infections has attracted considerable attention. In this study, we established the Qinling Mountains myxobacterial secondary metabolites library and a synergic assay in combination with ketoconazole against C. albicans was introduced for metabolites screening. Two active compounds with synergic anticandidal activities were obtained, which were identified as trans-resveratrol and cis-resveratrol. According to our study, resveratrol can reduce the dosage to 1/64 of ketoconazole as well as itraconazole. Furthermore, synergistic anticandidal activity of resveratrol combined with azoles was verified against a panel of clinical C. albicans isolates, and the combination strategy enhanced the azoles susceptibility of three fluconazole-resistant isolates. These findings suggest that resveratrol enhances the efficacy of azoles and provides a promising application in therapy of C. albicans infection.

Combined vaccination and immunostimulatory antibodies provides durable cure of murine melanoma and induces transcriptional changes associated with positive outcome in human melanoma patients

We have developed a recombinant adenovirus vaccine encoding dopachrome tautomerase (rHuAd5-hDCT) that produces robust DCT-specific immunity, but only provides modest suppression of murine melanoma. In the current study, an agonist antibody against 4-1BB was shown to enhance rHuAd5-hDCT efficacy and evoke tumor regression, but most tumors ultimately relapsed. The vaccine triggered upregulation of the immune inhibitory PD-1 signaling pathway and PD-1 blockade dramatically enhanced the rHuAd5-hDCT + anti-4-1BB strategy, resulting in complete regression of growing tumors in > 70% of recipients. The impact of the combined anti-4-1BB/anti-PD-1 treatment did not manifest as a dramatic enhancement in either the magnitude or functionality of DCT-specific tumor infiltrating lymphocytes relative to either treatment alone. Rather, a synergistic enhancement in intratumoral cytokine expression was observed, suggesting that the benefit of the combined therapy was a local event within the tumor. Global transcriptional analysis revealed immunological changes within the tumor following the curative vaccination, which extended beyond the T cell compartment. We identified an immune signature of 85 genes associated with clearance of murine melanoma that correlated with improved survival outcome in two independent cohorts of human melanoma patients. Our data reinforce the concept that successful vaccination must overcome local hurdles in the tumor microenvironment that are not manifest within the periphery. Further, tumor rejection following vaccination involves more than simply T cells. Finally, the association of our immune signature with positive survival outcome in human melanoma patients suggests that similar vaccination strategies may be promising for melanoma treatment.

A Transit Time-Resolved Microflow Cytometry-Based Agglutination Immunoassay for On-Site C-Reactive Protein Detection

An accurate and rapid microflow cytometry-based agglutination immunoassay (MCIA) suitable for on-site antibody or antigen detection was proposed. In this study, quantitative C-reactive protein (CRP) detection was chosen as a model assay in order to demonstrate the detection principle. The average transit time was employed to estimate the extent of the agglutination reaction and improve the detection accuracy as compared to the intensity-dependent methods. The detection time was less than 8 min. and only a 20 µL serum sample was needed for each test. The results showed a linear relationship between the average transit time of aggregates and CRP concentrations ranging from 0 to 1 µg/mL. The R² of this relationship was 0.99. The detection limit of this technology was 0.12 µg/mL CRP. The system used for CRP detection can be extended to also monitor other clinically relevant molecules.

De novo necroptosis creates an inflammatory environment mediating tumor susceptibility to immune checkpoint inhibitors

Cancer immunotherapies using monoclonal antibodies to block inhibitory checkpoints are showing durable remissions in many types of cancer patients, although the majority of breast cancer patients acquire little benefit. Human melanoma and lung cancer patient studies suggest that immune checkpoint inhibitors are often potent in patients that already have intratumoral T cell infiltrate; although it remains unknown what types of interventions can result in an intratumoral T cell infiltrate in breast cancer. Using non-T cell-inflamed mammary tumors, we assessed what biological processes and downstream inflammation can overcome the barriers to spontaneous T cell priming. Here we show a specific type of combination therapy, consisting of oncolytic virus and chemotherapy, activates necroptosis and limits tumor growth in autochthonous tumors. Combination therapy activates proinflammatory cytokines; intratumoral influx of myeloid cells and cytotoxic T cell infiltrate in locally treated and distant autochthonous tumors to render them susceptible to immune checkpoint inhibitors.

Workenhe et al. show in mice that a combination of oncolytic HSV-1 virus and Mitomycin-C activates an inflammatory response, through necroptosis induction, that renders tumours susceptible to immune checkpoint inhibitors. These findings informs on the potential role of necroptosis in immunotherapy approaches.

Effects of the Transverse Instability and Wave Breaking on the Laser-Driven Thin Foil Acceleration

Acceleration of ultrathin foils by the laser radiation pressure promises a compact alternative to the conventional ion sources. Among the challenges on the way to practical realization, one fundamental is a strong transverse plasma instability, which develops density perturbations and breaks the acceleration. In this Letter, we develop a theoretical model supported by three-dimensional numerical simulations to explain the transverse instability growth from noise to wave breaking and its crucial effect on stopping the acceleration. The wave-broken nonlinear mode triggers rapid stochastic heating that finally explodes the target. Possible paths to mitigate this problem for getting efficient ion acceleration are discussed.

Enhanced immunotherapeutic profile of oncolytic virus-based cancer vaccination using cyclophosphamide preconditioning

Despite a sizeable body of research, the efficacy of therapeutic cancer vaccines remains limited when applied as sole agents. By using a prime:boost approach involving two viral cancer vaccines, we were able to generate large tumor-specific CD8⁺ T-cell responses in a murine model of disseminated pulmonary melanoma. Significant increases in the number and quality of circulating effector T-cells were documented when low-dose cyclophosphamide (CTX) was administered pre-vaccination to tumor-bearing but not tumor-free hosts. Interestingly, tumor-bearing mice receiving CTX and co-primed with a melanoma differentiation antigen together with an irrelevant control antigen exhibited significantly enhanced immunity against the tumor, but not the control antigen, in secondary lymphoid organs. This result highlighted an increased cancer-specific reactivity of vaccine-induced T-cell responses following CTX preconditioning. Additionally, an acute reduction of the frequency of peripheral regulatory T-cells (Tregs) was noticeable, particularly in the proliferating, presumably tumour-reactive, subset. Enhanced infiltration of lungs with multifunctional T-cells resulted in overt reduction in metastatic burden in mice pretreated with CTX. Despite doubling the median survival in comparison to untreated controls, most vaccinated mice ultimately succumbed to cancer progression. However, preconditioning of the virus-based vaccination with CTX resulted in a remarkable improvement of the therapeutic activity leading to complete remission in the majority of the animals. Collectively, these data reveal how CTX can potentiate specific cellular immunity in an antigen-restricted manner that is only observed in vaccinated tumor-bearing hosts while depleting replicating Tregs. A single low dose of CTX enhances antitumor immunity and the efficacy of this potent prime:boost platform by modulating the kinetics of the vaccine-specific responses. Clinical assessment of CTX combined with next-generation cancer vaccines is indicated.

Virus shedding dynamics in asymptomatic and mildly symptomatic patients infected with SARS-CoV-2

Objectives

Asymptomatic patients, together with those with mild symptoms of coronavirus disease 2019 (COVID-19), may play an important role in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission. However, the dynamics of virus shedding during the various phases of the clinical course of COVID-19 remains unclear at this stage.

Methods

A total of 18 patients found to be positive for SARS-CoV-2 infection by real-time reverse transcription PCR (RT-PCR) assay and admitted to Chongqing University Central Hospital between 29 January and 5 February 2020 were enrolled into this study. Medical data, pulmonary computed tomographic (CT) scan images and RT-PCR results were periodically collected during the patients' hospital stay. All participants were actively followed up for 2 weeks after discharge.

Results

A total of nine (50%) asymptomatic patients and nine (50%) patients with mild symptoms of COVID-19 were identified at admission. Six patients (66.7%) who were asymptomatic at admission developed subjective symptoms during hospitalization and were recategorized as being presymptomatic. The median duration of virus shedding was 11.5, 28 and 31 days for presymptomatic, asymptomatic and mildly symptomatic patients, separately. Seven patients (38.9%) continued to shed virus after hospital discharge. During the convalescent phase, detectable antibodies to SARS-CoV-2 and RNA were simultaneously observed in five patients (27.8%).

Conclusions

Long-term virus shedding was documented in patients with mild symptoms and in asymptomatic patients. Specific antibody production to SARS-CoV-2 may not guarantee virus clearance after discharge. These observations should be considered when making decisions regarding clinical and public health, and when considering strategies for the prevention and control of SARS-CoV-2 infection.